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1.1 Vascular dementia 
Dementia is a decline in cognitive function to such extent that daily living is impaired.1 
Vascular lesions in the cerebrum can lead to this syndrome (vascular dementia, VaD) and is 
believed to be the most prevalent form after Alzheimer’s disease (AD).2 The incidence rates of 
VaD are highly dependent on age and vary between 1.5 and 3.3 per 1000 person-years in elderly 
populations.3-5 Typically, the clinical course is described by a stepwise progression. Cognitive 
deficits vary according to the site of the lesions but memory dysfunction is not the most 
prominent feature in most cases. Mental slowing and executive function disturbances are more 
pronounced.6 Focal neurological deficits, such as motor and sensory disturbances, can 
accompany the cognitive deficits. Ischemic vascular lesions leading to VaD are large vessel 
infarctions, lacunar infarctions and white matter hyperintensities (WMH).  
 
       
  A.       B.       C. 
Figure 1. A. FLAIR image of a left medial temporal lobe infarction. B. T1-weighted image of lacunar 
infarctions. C. FLAIR image of confluent WMH. 
 
 
1.2 White Matter Hyperintensities 
WMH are located in the subcortical white matter, where myelated fibers form 
connecting tracts between cortical and subcortical gray matter structures. Subtotal ischemic 
damage can lead to dysfunction of the fibers and cognitive decline. The exact mechanisms are 
still unknown but  disease of the small perforating vessels has been recognized as a causative 
factor.7 Older age and hypertension are among the most reported risk factors for small vessel 
disease.8-12 The dementia syndrome is of subcortical type and WMH can be visualized by 
computed tomography (CT) and especially magnetic resonance imaging (MRI). The use of 
cerebral MRI scanning has become more available, and has lead to more knowledge on the 
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incidence, radiological features, risk factors, and clinical implications of WMH. Not much is 
known at this time on the progression of the disease. However, longitudinal data are now 
becoming available.13 
 
 
1.3 Aim of thesis 
The aim of this thesis was twofold. First, in the last decade of the previous century a 
renewed interest in VaD rose among researchers. This was partly due to the fact that 
neuroimaging became more widely available and vascular lesions were visualized with high 
resolution. At first, relationship of the lesions with clinical features was hard to establish and 
only advancing age and hypertension were consistently found to be correlated. Among the 
reasons could be the heterogeneity of the lesions (cortical infarcts, lacunar infarcts, and WMH) 
and the fact that the vascular lesions can occur in any part of the brain, leading to a variety of 
(cognitive) symptoms. In general, dementia is considered a slowly progressive disease due to 
degeneration of neuronal cells, with several possible causes. VaD is not necessary slowly 
progressive (but can show a stepwise decline in cognitive function), and this might influence 
outcome of studies to the relationship between vascular disease and dementia. In this thesis, we 
set out to describe and discuss the different radiological appearances of vascular brain disease, 
and their relationship to vascular dementia and general vascular risk factors.  
Second, we focus on WMH, the subcortical subtotal vascular lesion type. They are a common 
observation in the elderly. A review published in 1995 on this subject reported an association 
with age, selective cognitive dysfunction and future stroke.14 Pathogenesis, pathological substrate 
and clinical significance were not completely understood. Furthermore, data on progression of 
the lesions over time were not yet available and prognostic value was unclear.15 Later, the profile 
of the cognitive deficits became more clear with mainly attention, executive functions, and 
visuospatial skills affected but again, longitudinal data were lacking.16 We set out to establish 
some methodological issues of WMH assessment (the correlation of WMH, as assessed with 
several methods, with clinical information and measurement of lesion change in time with 
different visual scales and a volumetric method) and correlation of WMH with longitudinal data 
(conversion from mild cognitive impairment (MCI) to AD). 
 
1.4 Outline of thesis 
Chapter 2.1 is an overview of the possible applications of neuroimaging in VaD. Also, 
different lesions and underlying diseases are discussed. In chapter 2.2 the radiological part of the 
NINDS-AIREN criteria and its interobserver variability are investigated. Use of different MRI 
General introduction 
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sequences for the detection of lesions in the thalamus, known for their effect on cognition, is 
evaluated in chapter 2.3. 
Chapter 3 focuses on the radiological features of WMH. Impact of scoring method on 
correlations with clinical characteristics (chapter 3.1) and on the detection of WMH progression 
in time (chapter 3.2) is described. 
In chapter 4, the radiologically assessed vascular lesions are correlated with vascular risk factors, 
symptoms and signs. Chapter 4.1 describes the role of WMH in the conversion from amnestic 
mild cognitive impairment (MCI) to Alzheimer’s disease and in chapter 4.2 risk factor profiles 
for large- and small vessel disease are assessed. Interpretation and discussion of the results of this 
thesis, as well as future directions, are presented in chapter 5. Chapter 6 consists of a brief 
summary.   
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Abstract 
 
 
 
Neuroimaging is necessary to demonstrate cerebrovascular disease (CVD) and is therefore an 
important examination in vascular dementia (VaD) and vascular cognitive impairment (VCI). 
MRI is preferred over CT because multiple planes and sequences are needed to assess various 
types of pathology in relevant regions. These protocols allow differentiation of VaD from other 
forms of dementia and sometimes identify specific underlying disorders. Different diagnostic 
criteria for VaD exist but the NINDS-AIREN criteria are widely used in controlled clinical trials 
in VaD. These criteria have relatively low sensitivity but are highly specific and include 
radiological requirements. The radiological criteria have poor interobserver agreement. In 
general, the radiological portion of the diagnostic criteria for VaD needs revision and refinement 
to include bone fide cases of VaD not currently accepted by imaging rules, and for the early 
detection of patients with VCI. 
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Introduction 
 
Dementia is rapidly becoming a major health care problem. Despite progress in the 
treatment of dementia, broader knowledge is needed for the development of more effective 
agents. Significant effort has resulted in clinical trials to investigate possible therapeutic agents 
on different groups of dementia patients.1-3 It is, therefore, important to be able to differentiate 
well between the different causes of dementia. 
In the past, brain imaging—computerized tomography (CT) and magnetic resonance imaging 
(MRI)—was regarded as an optional examination in patients with cognitive decline. It was used 
mainly to exclude surgically treatable causes of cognitive impairment, such as subdural 
hematoma, hydrocephalus and mass lesions. Recently, the focus has shifted from its use to rule 
out certain aetiologies, towards a supporting role for the clinical diagnosis with positive imaging 
findings.4 For all of the above reasons, it now appears desirable to obtain a structural brain scan 
at least once during the work-up of patients with cognitive decline.  
 
 
CT or MRI 
 
In the setting of a patient with cognitive decline, CT will generally suffice to rule out 
surgically treatable disorders. However, MRI is preferred to demonstrate specific types of 
pathologies, such as regionally specific atrophy, e.g. of the hippocampus in Alzheimer’s disease 
(AD), and presence of relevant vascular lesions. Reasons include its ability to reveal more detail 
and the greater capabilities to show subtle lesions in regions that are difficult to image with CT, 
such as the temporal lobe, but also the possibility to scan in different directions (e.g. coronal and 
sagittal). 
 
 
MRI protocols 
 
When the MRI scan is performed in a patient suspected of dementia, application of contrast 
material is not routinely indicated. The scanning protocol should include a coronal (3D) T1-
weighted series for the evaluation of the medial temporal lobe (MTL) and other regional patterns 
of atrophy. If cortical infarctions and lacunes are present, these can be seen using this sequence. 
In addition, axial Fluid-Attenuated Inversion Recovery (FLAIR) or dual- echo Turbo Spin Echo 
  
Chapter 2 
18
(TSE) images will reveal cortical infarcts and hypoxic/ischemic pathology (white matter 
hyperintensities or WMH).  
 
 
                        
A.     B. 
Figure 1. A. Infarction of the medial temporal lobe in the left hemisphere, FLAIR image.  
B. infarction in the parieto-temporal  association area, FLAIR image. 
 
                         
A.     B. 
Figure  2. A. Severe white matter hyperintensities in a patient with vascular dementia on  
FLAIR image. B. Extensive widened perivascular spaces, seen on FLAIR image. 
 
 
The use of FLAIR has the advantage of suppressing cerebrospinal fluid (CSF) signal, 
allowing a simple distinction of lacunes and perivascular spaces from WMH, both of which are 
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bright on standard T2-weighted (T)SE images. However, the reduced sensitivity of FLAIR in 
infratentorial lesions appears to extent to the diencephalon, and FLAIR should not be used in 
isolation since thalamic lesions may easily be missed.5 It may replace a proton-density type of 
image. Finally, axial T2* gradient echo images are useful to detect hemorrhages (microbleeds) 
and calcifications. 
 
 
Vascular dementia 
 
In vascular dementia (VaD), brain imaging can greatly add to the accuracy of the 
diagnosis and is the only way to determine the vascular cause of the dementia with certainty in 
vivo. Following the successful medication trials for AD, a number of controlled clinical trials 
were also completed for patients with VaD. A renewed interest in assuring a diagnosis of 
certainty has therefore developed. The most commonly used criteria for VaD in clinical trials 
require demonstration of lesions of cerebrovascular disease (CVD) with brain imaging; MRI 
being preferred over CT in patients with suspected VaD. It distinguishes better between ‘pure’ 
VaD and other forms of dementia, such as ‘mixed’ dementia (AD+CVD), as well as 
distinguishing between the different causes of VaD (e.g. CADASIL). Subcortical vascular 
lesions can be seen with higher sensitivity and therefore the severity of WMH can be better 
assessed. MRI is also superior in detecting the presence of microbleeds. 
 
 
Overview of diagnostic criteria for VaD 
 
Numerous sets of criteria for VaD have been proposed. The most widely used criteria 
are: DSM-IV, ADDTC, NINDS-AIREN, HIS and ICD-10.6-10 The DSM IV and the ICD-10 
criteria do not require brain imaging, whereas the ADDTC and NINDS-AIREN do require such 
direct evidence. The DSM-IV criteria are the most liberal, leading to high sensitivity but low 
specificity. On the other hand, the NINDS-AIREN are most specific but are not as sensitive. The 
ADDTC and HIS have intermediate sensitivity and specificity.11 The NINDS-AIREN criteria for 
VaD are the most recent and are widely used in randomized clinical trial on VaD at this time.  
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Characteristics of NINDS-AIREN criteria for vascular dementia 
 
The NINDS-AIREN criteria for VaD have three main features: a patient must be 
demented, have evidence of CVD on clinical examination and imaging, and fulfil a temporal 
relationship between onset of dementia relevant CVD. In order to assess the presence of CVD on 
the brain scan, a number of radiological features have been listed. In short, this radiological part 
of the criteria prescribes that vascular lesions should fulfil criteria for topography as well as 
severity. In case of large vessel stroke, the locations that meet criteria are: bilateral anterior 
cerebral artery, paramedian thalamic, inferior medial temporal lobe, parietotemporal and 
temporo-occipital association areas and angular gyrus, superior frontal and parietal watershed 
areas, as long as they involve the dominant hemisphere. In case of small vessel disease, lesions 
that fulfil criteria are: WMH more than 25% of the total white matter, multiple basal ganglia and 
frontal white matter lacunes and bilateral thalamic lesions. However, further specifications are 
missing and interobserver agreement is low, even after operationalization; further work is needed 
to increase the applicability of these criteria.12 
 
 
Territorial infarctions 
 
In VaD, cognitive impairment may result from large or small vessel disease. Following 
stroke localized in eloquent brain areas, dementia may emerge, especially when located in the 
dominant hemisphere. The clinical characteristics may indicate the location, but MRI and CT 
provide in vivo evidence for infarction, for example, in the medial temporal lobe. Criteria for 
VaD require stroke(s) in specific areas that can be easily depicted using neuroimaging. In 
selected cases, MR angiography (MRA) can be useful in the diagnosis in case of large vessel 
stroke. 
 
 
 
Findings in CADASIL 
 
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) can be diagnosed when a mutation in the NOTCH 3 gene on 
chromosome 19 is demonstrated. The diagnosis can also be made with typical pathological 
findings in skin or brain biopsies. When this information is not available, radiological criteria for 
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probable CADASIL have been shown to be quite sensitive and accurate. Early MRI findings 
include extensive symmetrical WMH involving the U-fibers at the vertex and the temporal pole; 
in later stages, involvement of the corpus callosum, external capsule, and development of 
multiple small lacunes and microbleeds may develop.13 
 
 
Findings in amyloid angiopathy 
 
Dementia is present is approximately 40% of cases of cerebral amyloid angiopathy 
(CAA). The clinical presentation of CAA is often with a lobar hemorrhage. The radiological key 
feature of CAA is the presence of microbleeds that can best be evaluated with gradient-echo 
scanning. This sequence may show multiple residues of petechial hemorrhages throughout the 
brain.14 
 
 
Conclusions 
 
Brain imaging is a crucial component in the evaluation of patients with VaD and VCI. 
MRI has a number of advantages over CT and currently is the examination of choice. The 
radiological portion of the NINDS-AIREN criteria has poor interobserver agreement and 
excludes some cases. Therefore, these radiological criteria need revision and refinement to 
include bone fide cases of VaD not currently accepted by imaging rules, and for the early 
detection of cases (e.g. vascular cognitive impairment).  
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Abstract 
 
 
Vascular dementia (VaD) is thought to be the most common cause of dementia after Alzheimer’s 
disease. The commonly used International Workshop of the National Institute of Neurological 
Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (AIREN) criteria for VaD necessitate evidence of vascular 
disease on CT or MRI of the brain. The purposes of our study were to operationalize the 
radiological part of the NINDS-AIREN criteria and to assess the effect of this operationalization 
on interobserver agreement. 
Six experienced and 4 inexperienced observers rated a set of 40 MRI studies of patients with 
clinically suspected VaD twice using the NINDS-AIREN set of radiological criteria. After the 
first reading session, operational definitions were conceived which were subsequently used in the 
second reading session. Interobserver reproducibility was measured by Cohen’s κ. 
Overall agreement at the first reading session was poor (κ=0.29) and improved slightly after 
application of the additional definitions (κ=0.38). Raters in the experienced group improved their 
agreement from almost moderate (κ=0.39) to good (0.62). The inexperienced group started out 
with poor agreement (κ=0.17) and did not improve (κ=0.18). The experienced group improved in 
both the large- and small-vessel categories, whereas the inexperienced group improved generally 
in the extensive white matter hyperintensities categories. 
Considerable interobserver variability exists for the assessment of the radiological part of the 
NINDSAIREN criteria. Use of operational definitions improves agreement but only for already 
experienced observers. 
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Introduction 
 
Vascular dementia (VaD) is thought to be the most common cause of dementia after 
Alzheimer’s disease. The reported incidence rates of VaD vary between 1.5 and 3.3 per 1000 
person-years in elderly populations.1-3 Incidence rates are highly dependent on age. The 
prevalence of VaD ranges from 1.0% in a population cohort ≥55 years of age to 4.2% in a cohort 
of subjects ≥71 years of age.4,5 Differences in diagnostic criteria may partly explain this 
variability. In 1993, the International Workshop of the National Institute of Neurological 
Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (AIREN) reported diagnostic criteria for the diagnosis of VaD 
for research studies.6 Criteria were formulated for the different parts of the diagnostic process 
(history and physical, radiological, and pathological examination) to classify patients as having 
possible, probable, and definite VaD. The NINDS-AIREN criteria state that the diagnosis of 
probable VaD cannot be made without some form of radiological assessment. Consequently, a 
list of lesions associated with VaD was included in the NINDSAIREN criteria. Recently, a vast 
interest in clinical trials on the efficacy of cholinesterase inhibitors and other drugs for VaD has 
emerged, and the NINDS-AIREN criteria with their radiological definitions are being used on a 
large scale in these trials. However, clear operational definitions on how to use and interpret the 
radiological criteria are lacking. Only a few interobserver studies of the NINDS-AIREN criteria 
have been published. In 2 of these studies, both clinical and radiological diagnoses were studied 
together.7,8 The agreement between raters was moderate to good (κ=0.42 in the first study 
mentioned, 0.46<κ<0.72 in the second study). It was suggested that a cause of the disappointing 
results could have been the difference in interpretation of the radiological criteria by the different 
raters.8 In this study, we examined the interobserver agreement of the radiological part of the 
NINDS-AIREN criteria and the effect of subsequently formulated operational definitions on the 
level of agreement in patients with clinical signs of VaD. Second, we investigated whether 
experienced and inexperienced raters would benefit equally from such definitions.  
 
 
Methods 
 
MRI Studies 
For this study, we selected MRI studies of patients with dementia and clinical signs of 
cerebrovascular disease. The selection was done to get 10 cases of large-vessel disease and 30 
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cases of small-vessel disease, reflecting the distribution in a recently completed trial on VaD.9 
Two authors who did not participate in the interobserver studies (E.C.W. van S., F.B.) performed 
the selection by applying the NINDS-AIREN criteria to the MRI scans. Based on the experience 
of an ~50% rejection rate in the above-mentioned trial and to have a balanced distribution in the 
study sample, MRI studies were selected in a way that we expected half of the scans to be rated 
as having sufficient abnormalities to fulfil the NINDS-AIREN criteria. It should be noted that the 
percentage of cases fulfilling such criteria is not reflective of the general population of patients 
clinically suspected of having VaD. In addition to the 40 scans, we selected 10 scans to be scored 
during the first assessment and to be used for consensus reading and formulation of definitions. 
All MRI studies consisted of axial T2, axial fluid-attenuated inversion recovery, and axial and 
coronal T1 series using 5-mm slices and 1x1-mm pixel size. 
 
Study Design 
Ten raters with different levels of experience evaluated the 40 selected MRI studies in 
2 consecutive reading sessions. The decision to use the same data set twice (rather than having 2 
independent data sets) was based on the expectation that this would preclude variability to be 
introduced by unbalanced matching in the distribution of cases over the various subcategories of 
the NINDS-AIREN criteria. On the other hand, we expected no bias from a learning effect when 
the same samples were rated twice because the second rating was done with a set of operational 
criteria developed from the additional training set of 10 scans; if any, this design would tend to 
maintain rather than to reduce interobserver variability and therefore is slightly conservative. The 
team of raters consisted of 10 physicians (2 radiologists, 4 neurologists, 3 research fellows, 1 
neurology resident). Six had extensive experience in the evaluation of vascular lesions on MRI 
scans in clinical settings or in population-based studies on aging and dementia. The other 4 had 
experience in assessing MRI scans of the brain, but they had never assessed vascular lesions 
systematically on a large scale. The raters were blinded to all clinical and personal information. 
During the first reading session, all raters individually assessed the scans 
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Table 1.  Scoring form of brain imaging lesions associated with VaD 
 
1.  TOPOGRAPHY 
Radiologic lesions associated with dementia  
include ANY of the following or combinations thereof: 
     
A.     Large vessel strokes in the following territories: left right both none 
 Anterior cerebral artery     
 Posterior cerebral artery, including:     
  Paramedian thalamic infarctions  
Inferior medial temporal lobe lesions 
    
 Association areas:      
  Parietotemporal 
Temporo-occipital 
Angular gyrus 
    
 Watershed carotid territories:     
 Superior frontal  
Parietal region 
  
   
B.     Small vessel disease:   yes no 
 Multiple basal ganglia and frontal white matter lacunae    
 Extensive periventricular white matter lesions    
 Bilateral thalamic lesions    
    
2. SEVERITY 
In addition to the above, relevant radiologic lesions associated with 
dementia include: 
 
 
 
yes 
 
no 
 Large vessel lesions of the dominant hemisphere     
 Bilateral large-vessel hemispheric strokes    
 Leukoencephalopathy involving at least ¼ of the total white 
matter 
   
    
Do the radiological findings fulfil the radiological criteria for VaD?  yes no 
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Table 2. Operational definitions of the imaging guidelines of the NINDS-AIREN criteria for Vascular 
Dementia 
 
 
 
TOPOGRAPHY 
Large vessel stroke:  Large vessel stroke is an infarction, defined as a parenchymal defect in 
an arterial territory, involving the cortical gray matter 
1) Anterior cerebral artery (ACA). Only bilateral ACA infarcts are sufficient to meet the 
NINDS-AIREN criteria 
2) Posterior cerebral artery (PCA). Infarcts in the PCA territory can only be included 
when they involve the following regions: 
a. Paramedian thalamic infarction: the infarct includes the cortical gray matter of 
the temporal/occipital lobe AND extends into the paramedian part (defined as 
extending to the third ventricle) of the thalamus; the extension may be limited 
to the gliotic rim of the infarct that surrounds the parenchymal defect 
b. Inferior medial temporal lobe lesions 
3) Association areas: a medial cerebral artery (MCA) infarction needs to involve the 
following regions: 
a. Parietotemporal: the infarct involves both the parietal and temporal lobe (e.g. 
angular gyrus) 
b. Temporo-occipital: the infarct involves both the temporal and occipital lobe 
4) Watershed carotid territories: A watershed infarction is defined as an infarct in the 
watershed area between MCA and PCA or between MCA and ACA, in the following 
regions: 
a. Superior frontal region 
b. Parietal region 
 Small vessel disease: Ischemic pathology resulting from occlusion of small perforating arteries 
may manifest itself as lacunes or white matter lesions. A lacune is defined as a lesion with 
CSF-like intensity on all sequences on MRI (water density on CT), surrounded by white matter 
or subcortical gray matter, larger than 2 mm. Care should be taken not to include Virchow-
Robin spaces, which typically occur at the vertex and around the anterior commisure near the 
substantia perforata. Ischemic white matter lesions are defined as circumscribed abnormalities 
with high signal on T2-weighted images not following CSF signal (mildly hypodens compared 
to surrounding tissue on CT), with a minimum diameter of 2 mm. 
1) Multiple basal ganglia and frontal white matter lacunes: The criteria are met when at 
least two lacunes in the basal ganglia region (including thalamus and internal capsule) 
AND at least two lacunes in the frontal white matter are present. 
2) Extensive periventricular white matter lesions: lesions in the white matter, abutting the 
ventricles and extending irregularly into the deep white matter, or deep/subcortical 
white matter lesions. Smooth caps and bands by themselves are not sufficient. Gliotic 
areas surrounding large vessel strokes should not be included here. 
3) Bilateral thalamic lesions: To meet the criteria, at least one lesion in each thalamus 
should be present. 
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SEVERITY 
1) Large vessel disease of the dominant hemisphere: If there is a large vessel infarct as 
defined above, to meet the criteria it has to be in the dominant hemisphere. In the 
absence of clinical information, the left hemisphere is considered the dominant one. 
2) Bilateral large vessel hemispheric strokes: One of the infarcts should involve an area 
listed under topography but is in the non-dominant hemisphere, while the one in the 
dominant hemisphere does not meet the topography criteria. 
3) Leukencephalopathy involving at least ¼ of the total white matter:  Extensive white 
matter lesions are considered to involve ¼ of the total white matter when they are 
confluent (grade 3 in the ARWMC scale) in at least two regions of the ARWMC 
scale and beginning confluent (grade 2 in the ARWMC scale) in two other regions. 
Note: a lesion is considered confluent when larger than 20 mm or consists of two or 
more smaller lesions that are fused by more than connecting bridges. 
 
FULFILMENT OF RADIOLOGICAL CRITERIA FOR PROBABLE VaD 
1) Large vessel disease: both the “topography” and “severity” criteria should be met (a 
lesion must be scored in at least one subsection of both “topography” and “severity” 
category). 
2) Small vessel disease: for white matter lesions, both the topography and severity 
criteria should be met (a lesion must be scored in at least one subsection of both 
“topography” and “severity” category); for multiple lacunes and bilateral thalamic 
lesions, only the topography criterion is sufficient. 
 
 
in random order with only the aid of the table of radiological findings of the NINDS-AIREN 
criteria for VaD as stated in the original article.6 All images were presented to the readers on 
identical personal computers using a digital viewing program, allowing window and level 
adjustment. The readers were able to browse through the scans as often as they wanted; no time 
limits were set. Scoring consisted of 2 stages. First, lesions had to be identified and classified 
topographically on a scoring form (Table 1), divided into a section on large-vessel disease 
(strategic infarcts in certain anterior, middle, or posterior cerebral artery territories) and a section 
on small-vessel disease (lacunes, white matter hyperintensities, bilateral thalamic lesions). 
Second, the topographical information had to be combined with severity criteria to decide 
whether the scan met the radiological criteria for VaD (final diagnosis). Subsequently, a joint 
consensus reading of the additional 10 scans was held, and operational definitions for scoring 
vascular lesions according to the NINDS-AIREN criteria were discussed. After consensus on a 
set of definitions was reached, a second reading of the 40 scans was performed the next day, 
again in random order, according to the newly formulated operational definitions (Table 2). 
 
Statistical Analysis 
We determined agreement between raters for the 2 reading sessions separately by 
Cohen’s κ for >2 raters.10,11 The weighted κ was not used because most scorings were 
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dichotomous and the different categories were not ordered. We did this using AGREE software 
(ProGAMMA), which also calculated standard error values. We determined κ for presence of 
radiological evidence for probable VaD, presence of large-vessel disease, and presence of small-
vessel disease. To test whether agreement between the first and second readings differed 
statistically, we determined z values for the difference in κ and used the corresponding 
probability value for testing. All scores were calculated for 3 groups: the whole group of raters 
(n=10), the group of experienced raters (n=6), and the group of inexperienced raters (n=4). A κ 
between 0 and 0.2 refers to poor agreement; 0.2 to 0.4, fair agreement; 0.41 to 0.60, moderate 
agreement; 0.61 to 0.80, good agreement; and 0.81 to 1.00, very good agreement.12 
 
 
Results 
 
Table 3 shows the results of the baseline readings. In 35.8% of all cases, a large-vessel 
infarction was scored; in 60.3% of cases, small-vessel disease was scored. This distribution was 
roughly as we expected. The percentage of cases in which the raters found vascular lesions that 
met the radiological criteria of the NINDS-AIREN was 41.3%, which again is in line with what 
we had anticipated. In Table 4, κ is given for the various sections of the scoring separately.  
At the first reading session, agreement in the group of inexperienced raters was 
generally less than the agreement in the group of experienced raters. This is also true for the 
assessment of the final diagnosis (Table 5).  At the first reading session, mean κ for the final 
diagnosis for all raters signifies fair agreement. After the first scoring, operational definitions 
were formulated in consensus (Table 2). During this consensus meeting, we identified the 
problems that had risen with the interpretation of the criteria. The meaning, exact location, and 
borders of a paramedian thalamic infarction were uncertain in our opinion. We had trouble 
interpreting the term “multiple basal ganglia and frontal white matter lacunes.” Questions that 
arose included, Are lacunes needed in both areas to meet the criteria? How many lacunes is 
“multiple” exactly? How big should an extensive periventricular white matter lesion be, and is a 
lesion considered only when directly abutting the ventricles? Should strokes in any area be 
considered in the bilateral large-vessel hemispheric strokes category, or only those strokes that 
are scored previously in the topography section? How can we approximate one fourth of the total 
white matter? We tried to address these questions in the operational criteria, leaving the original 
set of criteria fundamentally intact. Definitions were laid out for the different radiological types 
of vascular pathology, different regions of relevant strokes were defined, and for small-vessel  
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Table 3. Average number of times a lesion was scored by region (baseline scoring) 
 Mean number 
of times 
a lesion was scored 
SD % of all scans 
ACA infarction 1.3 1.3 3.3 
PCA infarction 7.3 7.9 18.3 
MCA association area infarction 7.6 2.0 19.0 
WSH infarction 5.8 2.9 14.5 
Total large vessel stroke 14.3 6.9 35.8* 
SVD1 16.6 11.0 41.5 
SVD2 18.4 7.2 46.0 
SVD3 3.9 2.9 9.8 
Total small vessel disease 24.1 10.1 60.3* 
SEV1 6.7 4.0 16.8 
SEV2 0.4 0.5 1.0 
SEV3 8.6 7.1 21.5 
Final diagnosis 16.5 8.5 41.3* 
ACA: anterior cerebral artery, PCA: posterior cerebral artery, MCA: medial cerebral artery, WSH: watershed 
region, SVD1: multiple basal ganglia and frontal white matter lacunes, SVD2: extensive periventricular 
white matter lesions, SVD3: bilateral thalamic lesions, SEV1: large vessel lesion in dominant hemisphere, 
SEV2: bilateral large vessel strokes, SEV3: leukencephalopathy involving at least ¼ of the total white matter  
*: Due to overlap in scores this figure is not just a summation of the sub-categories above 
 
 
disease, numeric definitions were adopted. With respect to the leukencephalopathy, we agreed 
on quantification with the use of the age-related white matter changes (ARWMC) rating 
scale.13 In the severity section, we discussed dominance of hemispheres, and for practical 
reasons, the left hemisphere was considered dominant. In addition to describing the different 
parts of the diagnostic criteria, rules on how to combine these parts were added because we 
noticed differences in opinion during consensus reading. We agreed that a scan would meet the 
final diagnosis of VaD if both severity and topography criteria were met, with the exception of 
the bilateral thalamic lesions and multiple lacunes subcategories, which have no related 
severity criterion. 
Table 4 shows that agreement generally increases, especially in the small-vessel 
category. To calculate significance of change in κ, z values were calculated. For appreciation of  
  
Chapter 2 
32
 
Table 4. Mean κ scores for first and second reading session by sub-category 
 
 Reading 
session 
κ of all raters      
(n = 10) 
κ of experienced 
raters  (n = 6) 
κ of inexperienced 
raters (n = 4) 
ACA 1 0.43 0.29 0.57 
 2 0.24 0.19 0.21 
PCA 1 0.11 0.35 0.06 
 2 0.08 0.69 0.06 
MCA 1 0.28 0.40 0.31 
 2 0.42 0.53 0.31 
WSH  1 0.39 0.44 0.23 
 2 0.38 0.47 0.15 
Mean large  1 0.30 0.37 0.29 
vessel stroke 2 0.28 0.47 0.18 
SVD1 1 0.13 0.30 0.03 
 2 0.21 0.46 0.04 
SVD2  1 0.47 0.51 0.39 
 2 0.67 0.64 0.74 
SVD3  1 0.38 0.56 0.10 
 2 0.25 0.56 0.08 
Mean small  1 0.33 0.46 0.17 
vessel disease 2 0.38 0.55 0.29 
SEV1  1 0.48 0.48 0.51 
 2 0.37 0.68 0.13 
SEV2  1 0.00 1.00 0.00 
 2 0.12 0.59 0.08 
SEV3  1 0.36 0.53 0.22 
 2 0.62 0.69 0.55 
 
ACA: anterior cerebral artery, PCA: posterior cerebral artery, MCA: medial cerebral artery, WSH: 
watershed region, SVD: small vessel disease, SVD1: multiple basal ganglia and frontal white matter 
lacunes, SVD2: extensive periventricular white matter lesions, SVD3: bilateral thalamic lesions, SEV1: 
large vessel lesion in dominant hemisphere, SEV2: bilateral large vessel strokes, SEV3: 
leukencephalopathy involving at least ¼ of the total white matter  
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Table 5. Mean κ (standard error) and differences in mean κ of the final diagnosis 
 
 All raters Experienced 
raters 
Inexperienced raters 
Mean ĸ reading session 1 (SE) 0.29 (0.05) 0.39 (0.05) 0.17 (0.06) 
Mean ĸ reading session 2 (SE) 0.38 (0.05) 0.62 (0.07) 0.18 (0.05) 
Difference κ reading  
sessions 1 and 2 
0.09              0.22     
 
0.01         
 
z-value 1.27 2.51 0.04 
p-value 0.20 0.01 0.97 
 
SE=standard error 
 
 
large-vessel disease, z values indicated that none of these differences are statistically significant. 
For small-vessel disease, only the difference in scoring of the inexperienced raters in the small-
vessel category showed statistically significant improvement (p=0.04). The mean κ for the final 
diagnosis for all raters at the second reading was slightly greater than at the first reading session 
(Table 5). For the experienced group, agreement rose to κ=0.62, but in the inexperienced group, 
it remained low. Only in the experienced group of raters did agreement improve significantly. 
 
 
Discussion 
 
We examined the interobserver agreement for the radiological assessment of the NINDS-AIREN 
criteria and quantified the added value of operational definitions. We found that overall 
agreement on the final diagnosis of VaD was only fair without guidelines, especially for 
inexperienced raters; this was true for the agreement in both the large- and small-vessel 
pathology categories. The large variability we found is in agreement with earlier studies on the 
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total set of criteria for VaD of the NINDS-AIREN and is in part the result of a lack of operational 
definitions for the radiological criteria. Already at the first scoring, several problems with the 
interpretation of those criteria arose. The weakest parts of the radiological criteria are those 
related to small-vessel disease, for which the original publication provides no details. This is 
especially unfortunate because these are the most prevalent types of pathology in patients with 
VaD. The raters also experienced difficulties in combining the individual parts of the criteria to 
make the final decision of VaD or not. Confusingly, the original criteria by the NINDS-AIREN 
list some of the topography characteristics in the severity section and vice versa. Additional 
definitions will not solve this problem because they do not actually change the original criteria. 
Taking this into consideration, we can explain low agreement. Our results suggest that a revision 
of the original criteria might be needed in this respect. After the application of operational 
definitions, agreement on the final diagnosis of VaD improved. However, stratified analysis 
showed that this improvement in agreement was confined to the group of experienced raters with 
a κ of 0.62, indicating good agreement. This was due to improvements in both the large- and 
small-vessel categories. In the group of inexperienced raters, agreement worsened in the large-
vessel category but improved in the small-vessel category. The latter was due mainly to an 
increase in κ by 0.35 to good agreement in the extensive white matter lesions subcategory.  
The design of this study has some limitations. We did not have a gold standard. The 
operational definitions were not validated against pathology or clinical findings but had the sole 
purpose of being practical, usable, and able to improve standardization. In addition, the raters did 
not have clinical information that could have contributed to the final diagnosis. In large clinical 
trials in which the MRI scans are rated centrally, this information is also not available, but 
agreement can be expected to improve in a clinical setting because previous studies show higher 
κ when this information is accessible by the readers. Another limitation of the study might have 
been the use of κ. In some cases, expected agreement was high because of the very low 
prevalence of some lesions, especially some stroke types (e.g., anterior cerebral artery, 
paramedian thalamic infarctions). This results in low κ even when agreement is high. Finally, the 
operational definitions formulated are, of course, arbitrary and may be subject to further 
amendments. However, the raters who formulated the criteria were the same raters who were 
going to apply them in the second reading session. It can therefore be expected that they were 
optimal for use in this interobserver study.  
In conclusion, we found that the radiological criteria for the NINDS-AIREN criteria for 
VaD are very complex. This makes these criteria less suitable for inexperienced raters and not 
appropriate for routine diagnosis on the basis of a standard radiological report only. The 
radiological criteria for the NINDS-AIREN criteria for VaD have suboptimal reproducibility. 
Characteristics of vascular dementia on imaging 
 35
Use of operational criteria improves agreement to acceptable levels, but only in experienced 
readers. Because operational definitions essentially do not change the original criteria, a critical 
reappraisal of the NINDS-AIREN radiological criteria seems to be needed to further improve the 
quality of the criteria and interobserver agreement. We hope that our results set the stage for such 
an endeavour. 
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Abstract 
 
The criteria of the National Institute of Neurological Disorders and Stroke (NINDS)–Association 
Internationale pour la Recherche et l’Enseignement en Neurosciences (AIREN) include thalamic 
lesions for the diagnosis of vascular dementia (VaD). Although studies concerning VaD and 
brain aging advocate the use of fluid-attenuated inversion recovery (FLAIR) or T2-weighted 
images (T2-WI) to detect ischemic lesions, none compared the sensitivity of these sequences to 
depict thalamic lesions. 
We performed a blinded review of T2-WI and FLAIR images in 73 patients fulfilling the 
radiological part of the NINDS-AIREN criteria (mean age, 71 years; range, 49 to 83 years). This 
sample was drawn from a large multicenter trial on VaD and was expected to have a high 
prevalence of thalamic lesions. In a side-by-side review, including T1-weighted images as well, 
lesions were classified according to presumed underlying pathology. 
The total number of thalamic lesions was 214. Two hundred eight (97%) were detected on T2-
WI, but only 117 (55%) were detected on FLAIR (χ2=5.1; P<0.05). Although the mean size of 
lesions detected on T2-WI and not on FLAIR (4.4 mm) was significantly lower than the mean 
size of lesions detected on both sequences (6.7 mm) (P<0.001), 5 of the 29 lesions >10 mm on 
T2-WI were not visible on FLAIR. FLAIR detected only 81 (51%) of the 158 probable ischemic 
lesions and 30 (60%) of the 50 probable microbleeds. 
FLAIR should not be used as the only T2-weighted sequence to detect thalamic lesions in 
patients suspected of having VaD. 
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Introduction 
 
In 1937, Papez1 described an anatomic circuit beginning and ending in the 
hippocampal formation possibly related to emotional experience. The projections of the Papez 
circuit involve the fornix, mammillary bodies, mamillothalamic tracts, anterior thalami, cingulate 
cortex, and cingulate bundles. The early notion that the Papez circuit subserves emotion has been 
abandoned and replaced by the proposal it is primarily involved in mnemonic functions. Lesions 
of the major components of this circuit have been shown to disrupt memory in humans, 
particularly those localized in the anterior group of thalamic nuclei.2-6 However, lesions affecting 
other thalamic components or connections not considered in the circuit, such as the mediodorsal 
(dorsomedial), intralaminar, and pulvinar nuclei or the thalamofrontal networks, may also cause 
cognitive deficits and marked behavioral changes.2,7-11 MRI and CT are crucial for the diagnosis 
of cerebrovascular diseases. The first studies using CT for the evaluation of brain lesions in 
patients with ischemic stroke confirmed the importance of thalamic infarctions as a cause of 
dementia.12,13 Therefore, the criteria of the National Institute of Neurological Disorders and 
Stroke (NINDS)–Association Internationale pour la Recherche et l’ Enseignement en 
Neurosciences (AIREN) include radiological evidence of thalamic lesions for the diagnosis of 
probable vascular dementia (VaD).14 Moreover, a single thalamic infarction may induce VaD.15 
MRI studies concerning VaD and brain aging advocate the use of fluid-attenuated inversion 
recovery (FLAIR) or T2-weighted images (T2-WI) to detect and characterize brain 
abnormalities.16-18 However, to our knowledge no comparative study was performed to assess 
which MRI sequence yields the highest sensitivity for thalamic lesions. In this study we sought to 
compare the sensitivity of each of these sequences to depict thalamic lesions in patients with 
VaD. 
 
 
Subjects and Methods 
 
Patients 
The subjects were derived from cases belonging to the VantagE study, a multicenter, 
phase III, prospective, randomized, double-blind clinical trial on the effects of rivastigmine in 
patients with VaD. For the present study we selected a sample of 73 patients (mean age, 71 
years; range, 49 to 83 years) fulfilling the radiological part of the NINDS-AIREN criteria.14 On 
the basis of earlier central reading of the images for trial inclusion, we knew that approximately 
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75% of the current sample might be expected to have either unilateral or bilateral focal thalamic 
lesions. To avoid any clinical bias, we were blinded to all clinical and center data of the patients.  
 
MRI Technique 
The patients were scanned on different scanners operating from 0.5 to 1.5 T. Axial T2 
spin-echo weighted images (echo time [TE] 80 to 120 ms, repetition time [TR] 3000 to 4000 ms, 
slice thickness 5 mm); axial FLAIR (TE 110 to 150 ms, TR 9000 to 10000 ms, inversion time 
2000 to 2200 ms, slice thickness 5 mm); and axial, sagittal, and coronal T1 spin-echo weighted 
images (TE 11 to 20 ms, TR 500 to 700 ms, slice thickness 5 mm) were acquired. To maintain 
blinding, we were restricted from access to information about the type of the scanner used for 
each particular patient as well as the location of the imaging center. 
 
Image Assessment 
The initial assessment was performed in a blinded way, in which the T2-WI and 
FLAIR images were evaluated in pseudorandom order, with the use of 16-bit digital imaging 
files. All lesions were marked and numbered with digital overlays. We included only focal 
thalamic abnormalities >1 mm and excluded those suggestive of perivascular spaces. 
Perivascular spaces were defined as sharply demarcated areas with a signal isointensity relative 
to cerebrospinal fluid (CSF), following the course of a perforating vessel on sagittal or coronal 
images.19 Care was also taken to avoid the inclusion of pulsation artifacts, recognizable by linear 
patterns of signal banding due to phase misregistration. For further subtyping and analysis, T2-
WI, FLAIR, and T1-weighted images (T1-WI) were evaluated side by side. The greatest 
dimension of each focal abnormality was measured, and all were classified on each of the 3 
imaging sequences in the following categories: hyperintense, hypointense, predominantly 
hypointense (hypointense with a small hyperintense component), and hypointense with a 
peripheral rim of hyperintensity. 
 
Statistical Evaluation 
Statistical analysis was performed with the use of SPSS 11.0. We used χ2 statistics to 
compare categorical data, such as proportions of lesions detected by each sequence. For 
comparisons of continuous variables, Student’s t test was applied because the data were normally 
distributed. 
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Results 
 
The total number of focal thalamic lesions detected was 214. One hundred twenty-four 
(58%) of the 214 measured <5 mm, 61 (29%) between 5 and 10 mm, and 29 (14%) >10 mm. 
One hundred nine (51%) were localized in the right thalamus and 105 (49%) on the left. Two 
hundred eight (97%) of the 214 lesions were identified on T2-WI, but only 117 (55%) were 
detected on FLAIR (χ2=5.1; P<0.05). Almost half (47%) of the lesions found on T2-WI were not 
detected on FLAIR (Table 1).  
Although the mean size of lesions detected on T2-WI and not on FLAIR (4.4 mm) was 
significantly lower than the mean size of lesions detected on both sequences (6.7 mm) (P<0.001), 
5 of the 29 lesions >10 mm on T2-WI were not visible on FLAIR (Table 2). 
One hundred eight (50%) of the lesions were hyperintense on T2-WI and hypointense 
on T1-WI and probably correspond to infarctions. Fifty lesions (23%) were hyperintense on T2-
WI and isointense on T1-WI and may correspond to areas of myelin pallor. Fifty lesions (23%) 
were hypointense on T2-WI and T1-WI and probably represent microbleeds (hemorrhagic 
lacunae).  
FLAIR detected 61 (56%) of the 108 probable infarctions, 30 (60%) of the 50 probable 
microbleeds, and 20 (40%) of the 50 probable areas of myelin pallor. Thirty-two of the probable 
infarctions were hyperintense on FLAIR (incomplete or noncystic infarctions), and 29 were 
totally or partially hypointense (cystic and partially cystic infarctions). The vast majority (79%) 
of the 97 lesions not detected on FLAIR were hyperintense on T2-WI (Table 3). 
 
 
Discussion  
Our study shows that FLAIR imaging is not very sensitive in detecting focal thalamic 
lesions and is therefore not well suited as a stand-alone sequence in the evaluation of patients 
suspected of VaD. FLAIR sequences employ a long inversion time that suppresses the signal 
from CSF and a long TE that provides heavy T2 weighting.
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Table 1. Lesions on T2-WI and FLAIR 
                                                        Signal on T2-WI 
  Not 
detected 
Hyperintense Hypointense Total 
Signal on FLAIR      
 Not Detected  0 77 20 97 
 Hyperintense  3 49 0 52 
 Hypointense  3 14 30 47 
 Predominantly hypointense  0 5 0 5 
 Hypointense with 
hyperintense rim 
 0 13 0 13 
 Total  6 158 50 214 
 
 
Table 2. Detection on FLAIR and Distribution by Size of Focal Lesions on T2-WI 
                                                                                 Detection on FLAIR 
 Not Detected Detected Total 
Size on T2-WI    
 1–5 mm 66 53 119 
 5–10 mm 26 34 60 
 >10 mm 5 24 29 
 
 
Table 3. Detection on FLAIR and Signal on T2 and T1-WI 
 Detected on FLAIR Not Detected on FLAIR  
 Hyperintense 
on T2-WI 
Hypointense 
on T2-WI 
Hyperintense 
on T2-WI 
Hypointense 
on T2-WI 
 
Isointense  
on T1-WI 
20 10 30 13 Χ=0.079 
P=0.779 
Hypointense  
on T1-WI 
61 20 47 7 Χ=2.785 
P=0.095 
Total 81 30 77 20 Χ=1.164 
P=0.281 
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Therefore, the major interest of FLAIR is to detect and characterize brain lesions around CSF 
spaces.20,21 Most studies advocate superiority of FLAIR over conventional spin-echo imaging in 
a wide range of pathologies.22-32 FLAIR images also have the advantage of easily identifying 
CSF-like lesions.33 Some studies showed that FLAIR was more often associated with image 
artifacts or could not corroborate the aforementioned superiority of FLAIR.31,34,35 Disadvantages 
of FLAIR include a reduced sensitivity to detect infratentorial or spinal cord lesions.35-38 The 
reason for this is unknown but most likely reflects different relaxation characteristics in those 
regions, both in normal-appearing tissue and in lesions. For example, T1 and T2 relaxation times 
of infratentorial lesions in patients with multiple sclerosis are closer to the relaxation times of 
local normal-appearing white matter than those of supratentorial lesions, resulting in reduced 
contrast between posterior fossa lesions and the background.39 Age-related increases in T1 
relaxation times of human brain also have been shown, particularly in the thalami,40 and may 
serve to explain the lack of sensitivity of FLAIR for thalamic lesions in elderly patients with 
VaD. Alternatively, the occurrence of cystic changes in lacunar infarctions41 will lead to a 
prolongation of T1 relaxation time, and the signal from these lesions may be suppressed, as in 
CSF spaces. The same may occur with multiple sclerosis lesions severely hypointense on T1-
WI.42 MRI-pathological correlation studies performed to determine the background of age-
related subcortical gray and white matter hyperintensities on T2-WI found different types of 
pathology: infarctions, gliosis, myelin and axonal loss, breakdown of the ependymal lining, and 
enlarged perivascular spaces.17,43-47 Areas of myelin pallor can be hyperintense on T2-WI but 
isointense on T1-WI,17,46 and it seems possible that differences in type of pathology can also 
influence detection on FLAIR. Although the proposed neuropathological classification of 
lacunae includes both ischemic (type I) and hemorrhagic (type II) vascular abnormalities and 
enlarged perivascular spaces (type III),41 in VaD it is important to differentiate the vascular 
lesions. MRI-pathological correlation studies found that the great majority of enlarged 
perivascular (Virchow- Robin) spaces normally surround perforating arteries that enter the 
striatum in the anterior perforated substance, just above the internal carotid artery bifurcation and 
lateral to the anterior commissure. They are responsible for the so-called état criblé of the basal 
ganglia19,48-52 and are much less frequently located in the thalami.52 Therefore, it is unlikely that 
those lesions classified as cystic infarctions on the basis of MRI are in fact Virchow-Robin 
spaces or could account for the greater number of lesions detected on T2-WI. Actually, FLAIR 
performed more poorly for all types of presumed pathology. A limitation of our study is that we 
used images acquired on a wide range of scanners and sequences, not all of which may be 
optimally tuned. On the other hand, this reflects the normal variability of vendor-supported 
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sequences, and given the more complex contrast mechanisms in FLAIR, these may be less stable 
than for T2-WI. For the detection of type II hemorrhagic lacunae,53,54 both spin-echo and FLAIR 
are insensitive compared with T2*-WI gradient-echo sequences,55,56 but these were not available 
in the context of this trial. Nevertheless, we detected a fair amount of probable microbleeds. In 
conclusion, the accuracy of T2-WI for the detection of thalamic lesions in patients with probable 
VaD is far superior to FLAIR. Given the great clinical importance of these lesions, FLAIR 
should not be used as the only T2-weighted sequence in patients suspected of having VaD. In 
addition to the posterior fossa and spinal cord, the diencephalon seems to represent another 
region not suitable for evaluation by FLAIR MRI. 
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Abstract 
 
White matter hyperintensities (WMH) are associated with decline in cognition, gait, mood, and 
urinary continence. Associations may depend on the method used for measuring WMH. We 
investigated the ability of different WMH scoring methods to detect differences in WMH load 
between groups with and without symptoms. 
We used data of 618 independently living elderly with WMH collected in the Leukoaraiosis And 
DISability (LADIS) study. Subjects with and without symptoms of depression, gait disturbances, 
urinary incontinence, and memory decline were compared with respect to WMH load measured 
qualitatively using 3 widely used visual rating scales (Fazekas, Scheltens, and Age-Related 
White Matter Changes scales) and quantitatively with a semiautomated volumetric technique and 
an automatic lesion count. Statistical significance between groups was assessed with the χ2 and 
Mann–Whitney tests. In addition, the punctate and confluent lesion type with comparable WMH 
volume were compared with respect to the clinical data using Student t test and χ2 test. Direct 
comparison of visual ratings with volumetry was done using curve fitting. 
Visual and volumetric assessment detected differences in WMH between groups with respect to 
gait disturbances and age. WMH volume measurement was more sensitive than visual scores 
with respect to memory symptoms. Number of lesions nor lesion type correlated with any of the 
clinical data. For all rating scales, a clear but nonlinear relationship was established with WMH 
volume. 
Visual rating scales display ceiling effects and poor discrimination of absolute lesion volumes. 
Consequently, they may be less sensitive in differentiating clinical groups.  
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Introduction  
 
White matter hyperintensities (WMH) on MRI are associated with cognitive 
dysfunction, gait abnormalities, falls, and depression and contribute to disability in the elderly 
population.1-5 Lesion load on MRI may serve as surrogate marker of disease burden and may 
ultimately guide treatment. For the measurement of WMH extent, different methods can be used, 
ranging from visual rating to fully computerized techniques. Visual rating of WMH is easy, and 
several scales are available with good reproducibility.6 The visual scales often do not detail size 
and location, and most are not linear. Scores from different rating scales are not directly 
comparable.7 Most volumetric studies use supervised semiautomated methods that may provide 
more information on location and size, as well as continuous data, but are time consuming.8,9 
Both methods have been used to correlate WMH with clinical data and have rendered varying 
results.10,11 Subjective memory symptoms, although difficult to define, are associated with higher 
risk of dementia and WMH and may be used for the early detection of subjects at risk.12 Number 
of lesions and lesion pattern (punctate versus confluent) may also be correlated to clinical data. 
WMH burden might be caused by a large number of punctate lesions or few confluent lesions, 
possibly leading to different clinical signs. 
In this study, we aimed to establish cross-sectionally the sensitivity of several visual 
WMH scales, volumetric WMH measurement, as well as WMH lesion count and pattern, to 
symptoms of cognitive decline, gait abnormalities, urinary incontinence, and depression. The 
relationship between visual and volumetric methods was characterized by establishing the 
mathematical function that best fitted the data. The study group consisted of elderly 
independently living individuals recruited on the basis of WMH and stratified by lesion severity 
into 3 groups. 
 
 
Materials and Methods 
 
Subjects 
Data were drawn from the multinational multicenter longitudinal Leukoaraiosis And 
DISability (LADIS) study among 639 elderly, described previously.13 Inclusion criteria were 65 
to 85 years of age and no or mild disability in everyday life (as established with the Instrumental 
Activities of Daily Living scale).14 Subjects were required to have at least some degree of WMH, 
demonstrated on MRI. Participants presented for evaluation in various settings: stroke unit, 
memory clinic, neurological or geriatric wards/clinic, population studies on aging, controls in 
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other studies. The study was approved by the local ethics committees, and all subjects gave 
informed consent. At baseline, subjects underwent a standardized evaluation (including global 
functioning, cognitive, motor, and psychiatric assessment), and, together with their informants, 
filled in questionnaires on medical history. The data used in this study are age, gender, presence 
of depression requiring therapy, symptoms of urinary incontinence, gait disturbances, and 
memory problems, as expressed by the participants or their informants. 
 
MRI Scans 
All subjects underwent magnetic resonance scanning following a standard protocol, 
during which 0.5-T or 1.5-T scanners were used and series included axial T2-weighted images 
(echo time [TE] 100 to 120 ms; repetition time [TR] 4000 to 6000 ms; voxel size 1x1x5 to 7.5 
mm3; 19 to 24 slices), axial fluid-attenuated inversion recovery (FLAIR) images (TE 100 to 140 
ms; TR 6000 to 10 000 ms; inversion time 2000 to 2400 ms; voxel size 1x1x5 to 7.5 mm3; 19 to 
24 slices), and coronal or sagittal 3D T1 sequence (TE 4 to 7 ms; TR 10 to 25 ms; flip angle 15 to 
30°; voxel size 1x1x1 to 1.5 mm3). All scans were checked and stored at the Image Analysis 
Center of the VU Medical Center, Amsterdam, the Netherlands. Postprocessing and data analysis 
for this study was performed in Amsterdam and Copenhagen. Of the 639 scans, 21 could not be 
used because of insufficient quality for the volumetric assessment. 
 
Visual Rating 
On the FLAIR images, we applied the visual rating scales of Fazekas (range 0 to 3), 
Scheltens (range 0 to 84), and the Age-Related White Matter Changes (ARWMC) scale (range 0 
to 30).15-17 All ratings were performed by an experienced rater (E.vS.) blind to the clinical data.  
 
Volumetric Assessment 
Volumetric analysis of WMH was performed by a single rater on the same axial 
FLAIR images, including the infratentorial region, using a Sparc 5 workstation (SUN). Lesions 
were marked and borders were set using local thresholding (home-developed software 
Show_Images, version 3.6.1) on each slice. No distinction was made between subcortical and 
periventricular hyperintensities. Areas of hyperintensity on T2-weighted images around 
infarctions and lacunes were disregarded. 
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Lesion Count 
An automated assessment of the number of lesions was performed by defining each 
lesion that was generated with the volumetric method, as a cluster of 3D connected voxels, and 
counting the number of such clusters (26-connectivity). 
 
Reliability Assessment 
To test reproducibility of the different methods, 18 scans, with a mean volume (SD) of 
26.3 (19.0) mL, were assessed twice with an interval of >2 months. 
 
Statistical Analysis 
Sensitivity of WMH measurements to detect clinical group differences was tested with χ2 for 
trend (Fazekas scale) and Mann–Whitney test (Scheltens scale, ARWMC scale, volumetric 
measurement, and lesion count). Nonparametric testing was used for the WMH volumes because 
of the nonnormal distribution. Differences in lesion volume and number between Fazekas groups 
were tested using ANOVA with Bonferroni correction. To test the hypothesis that lesion type 
(punctate, defined as Fazekas score 1, versus confluent, defined as Fazekas score 3, with 
comparable lesion volumes) was associated with clinical characteristics, we selected all subjects 
with WMH volume between 15 and 30 mL. In this volume range, both Fazekas scores 1 and 3 
were represented. These groups were compared with respect to the clinical data, using the 
Student t test and χ2 test. Visual rating scales were correlated with the volumetric method using 
Spearman rank correlation method. To test the hypothesis of a nonlinear relationship between the 
visual methods and the volumetric method, we fitted a linear and a quadratic function to the plot 
using a linear regression with a correction factor based on the local variance.18  
 
 
Results 
 
WMH Load and Clinical Data  
Table 1 shows mean WMH volumes and scores for different subject groups. Mean 
WMH volumes, but not visual ratings, were significantly greater in men than in women. Both 
visual and volumetric assessments showed group differences in WMH load between the older 
and younger subjects. No significant differences in WMH load could be found between the 
groups with and without a history of depression or symptoms of urinary incontinence. The mean 
WMH load of subjects with symptoms of gait disturbance was only significantly larger when 
measured volumetrically or with the ARWMC and Scheltens scales. With the volumetric  
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assessment only, we were able to establish a significant difference in lesion load between 
subjects with and without memory symptoms.  
 
Mean Lesion Volume and Lesion Count 
Fazekas score 1 corresponded to a mean lesion volume of 0.20 mL, score 2 to 0.45 mL 
per lesion and score 3 to 1.26 mL per lesion (Table 2). The differences were statistically 
significant between all groups. Table 2 also shows mean total WMH for each Fazekas category, 
which was also statistically significant between the groups. Subjects in the Fazekas score 2 
category tended to have most lesions. Number of lesions did not discriminate significantly 
between groups with and without symptoms (Table 1).  
 
 
Table 2. Lesion characteristics for each Fazekas category 
 Fazekas 1 Fazekas 2 Fazekas 3 
Mean volume per lesion, ml (SD)† 0.20 (0.1) 0.45 (0.4) 1.26 (1.0) 
Mean WMH volume, ml (SD)† 6.49 (4.7) 18.83 (7.7) 51.35 (26.1) 
Mean number of lesions (SD)† 33.2 (18) 53.6 (25) 51.0 (24) 
 
 
Table 3. Differences in a group of subjects with WMH volume 15 - 30 ml 
 Fazekas 1  Fazekas 3  p-value 
Total subjects 17 29  
Mean Age (years) 74.4 73.2 0.47* 
% Male 58.8 37.9 0.2† 
% History of depression 29.4 27.6 0.9 † 
% Urinary incontinence 
complaints 
29.4 20.7 0.5 † 
% Gait disturbance 
complaints 
41.2 62.1 0.1 † 
% Memory complaints 82.4 58.6 0.1 † 
*: Student’s t-test 
†:Chi-square 
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Lesion Pattern 
We found no significant differences in clinical features between the groups with 
punctate (Fazekas 1) and confluent (Fazekas 3) lesions (Table 3). 
 
Correlation Between Visual Rating Scales and Volumetric Measurement 
Scatter plots for the Fazekas and ARWMC scales with WMH volume are shown in figures 1 and 
2. The scatter and shape of the plot for the Scheltens score was similar to the scatter plot of the 
ARWMC score (data not shown). Increasing volume correlated with higher visual scores 
(Spearman ρ 0.86), and scatter increased with higher WMH visual scores. The relationship with 
WMH volume was better described by a quadratic than a linear model, indicated by higher R2 
(Table 4). When corrected for difference in variance, the difference between the linear and 
quadratic model was statistically significant (P<0.01).  
 
 
 
 
 
Figure 1. 
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Figure 2. 
 
Intraobserver Reliability 
Intrarater agreement for the scales was good with a κ for  Fazekas score of 0.84. 
Intraclass correlation coefficients were 0.93 (ARWMC scale), 0.92 (Scheltens scale), and 0.99 
(volume measurement). The mean difference between the 2 measurements was not statistically 
significant when tested against 0 using a 1-sample t test. 
 
Table 4. Mathematical models of the relationship between visual rating scales and WMH volume 
 
Model R
2 
Fazekas scale linear 0.58 
 quadratic      0.62* 
ARWMC scale linear      0.67 
 quadratic      0.71* 
Scheltens scale linear      0.60 
 quadratic      0.63* 
*: difference significant at the 0.01 level 
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Discussion 
 
The results indicate that volumetry may be more sensitive to detect small group 
differences. This is in line with previous research, correlating WMH measurement methods with 
cognitive performance.19 Subjective and objective memory symptoms are not interchangeable for 
the assessment of cognition, but both seem to be related with WMH. The best method for the 
measurement of WMH with respect to objective cognitive measures is still to be established. The 
ARWMC and Scheltens rating scales have a greater range than the Fazekas scale and were found 
to differentiate better between groups. This finding corresponds with a review on the relationship 
between WMH and cognition.20 The Fazekas scale seems most appropriate for defining different 
WMH groups. No group differences were detected for symptoms of urinary incontinence and 
depression. One of the reasons could be that only WMH in certain areas correlate with these 
symptoms. Frontal WMH has been associated with mood disorders, cognitive functions, and gait 
problems. On the other hand, it was shown that WMH in different regions are highly correlated 
and that their influence on clinical signs may therefore not be limited to certain areas of the 
brain.21 To our knowledge, this is the first report on lesion count as a measure of WMH severity. 
We found that it was not sensitive to detect associations with clinical signs, possibly because 
lesion count does not take into account lesion size. In progressing disease, lesions can merge, 
leading to a smaller total number of lesions. Few lesions could therefore indicate either mild or 
severe disease. This lack of correlation between number of lesions and clinical findings was also 
found in individuals with multiple sclerosis (MS). This caused studies in MS to focus on total T2 
lesion volume and T1 gadolinium enhancing lesions instead of number of lesions.22,23 We 
compared subjects with punctiforme and confluent lesion patterns who had comparable WMH 
volumes. We found no differences in symptoms between the groups. Although these subanalyses 
limited the number of subjects studied, it illustrates the arbitrary nature of the qualitative scoring 
system. We confirmed the good correlations between all three visual rating scales and the WMH 
volume, but the current study shows that the variability in WMHvolume is large in the patient 
groups with high visual scores.24 Subject group with higher visual scores contains subjects with 
different degrees of WMH burden, leading to decreased correlation with clinical data. When 
progression of WMH is measured, this ceiling effect can be even greater. A previous study on the 
detection of WMH progression with conventional visual rating scales showed lack of sensitivity 
compared with WMH volume measurement.25 This effect is especially of interest because WMH 
progression seems to occur fastest in patients with a high lesion load.26 The WMH volume in this 
study was significantly higher than reported in previous studies.27,28 The LADIS study was 
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designed to enroll a large population of subjects with WMH, and participants were stratified into 
three categories of WMH severity. This approach is different from population-based studies and 
resulted in a relatively large group of subjects with a high WMH lesion load. Results are 
therefore not directly applicable to the healthy elderly population. The advantage of this design is 
the possibility of studying a broad spectrum of lesion loads. WMH burden can be presented as 
volume or as a proportion of the total white matter or intracranial volume, depending on the 
focus of the study. This makes comparison between studies complicated. We did not correct for 
intracranial volume or white matter volume because we wanted to compare the raw volumes with 
visual scales that are also uncorrected. Wen and Sachdev investigated uncorrected WMH volume 
and found no differences in WMH volumes between men and women, whereas in our study, men 
had a larger mean WMH volume than women.29 The subjects in their study were younger than 
our study participants (60 to 64 years versus 65 to 85 years), which could partly explain this 
difference. We did not control for risk factors for WMH such as hypertension. In addition, 
objective measures for cognition, gait, depression, and urinary incontinence were also not 
included here. This was done because the focus of this study was not to establish a causal 
relationship of WMH with clinical data but a comparison between scoring methods in their 
association with symptoms, which is clearly of clinical relevance for clinicians dealing with these 
patients. 
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Appendix 
Participating Centers and Personnel 
Helsinki, Finland (Memory Research Unit, Department of Clinical Neurosciences, Helsinki 
University): Timo Erkinjuntti, MD, PhD, Tarja Pohjasvaara, MD, PhD, Pia Pihanen, MD, Raija 
Ylikoski, PhD, Hanna Jokinen, LPsych, Meija-Marjut Somerkoski, MPsych; Graz, Austria 
(Department of Neurology and MRI Institute, Karl-Franzens University): Franz Fazekas, MD, 
Reinhold Schmidt, MD, Stefan Ropele, PhD, Brigitte Rous, MD, Katja Petrovic, Ulrike Garmehi; 
Lisboa, Portugal (Servic¸o de Neurologia, Centro de Estudos Egas Moniz, Hospital de Santa Maria): 
Jose´ M. Ferro, MD, PhD, Ana Verdelho, MD, Sofia Madureira, PsyD; Amsterdam, The Netherlands 
(Department of Neurology, VU Medical Center): Philip Scheltens, MD, PhD, Ilse van Straaten, MD, 
Wiesje van de Flier, PhD, Frederik Barkhof, MD, PhD; Goteborg, Sweden (Institute of Clinical 
Neuroscience, Goteborg University): Anders Wallin, MD, PhD, Michael Jonsson, MD, Karin Lind, 
MD, Arto Nordlund, PsyD, Sindre Rolstad, PsyD, Kerstin Gustavsson, RN; Huddinge, Sweden 
(Karolinska Institute, Department of Clinical Neuroscience and Family Medicine, Huddinge 
University Hospital): Lars-Olof Wahlund, MD, PhD, Militta Crisby, MD, PhD, Anna Pettersson, 
physiotherapist, Kaarina Amberla, PsyD; Paris, France (Department of Neurology, Hopital 
Lariboisiere): Hugues Chabriat, MD, PhD, Ludovic Benoit, MD, Karen Hernandez, Solene Pointeau, 
Annie Kurtz, Daniel Reizine, MD; Mannheim, Germany (Department of Neurology, University of 
Heidelberg, Klinikum Mannheim): Michael Hennerici, MD, Christian Blahak, MD, Hansjorg 
Baezner, MD, Martin Wiarda, PsyD, Susanne Seip, RN; Copenhagen, Denmark (Memory Disorders 
Research Unit, Department of Neurology, Rigshospitalet and Danish Research Center for Magnetic 
Resonance, Hvidovre Hospital, Copenhagen University Hospital): Gunhild Waldemar, MD, DMSc, 
Egill Rostrup, MD, MSc, Charlotte Ryberg, MSc; Tim Dyrby; Newcastle-on-Tyne, UK (Institute for 
Ageing and Health, University of Newcastle): John O’Brien, DM, Sanjeet Pakrasi, MRCPsych, Thais 
Minnet, PhD, Michael Firbank, PhD, Jenny Dean, PhD, Pascale Harrison, BSc, Philip English, DCR. 
The coordinating center is in Florence, Italy (Department of Neurological and Psychiatric Sciences, 
University of Florence): Domenico Inzitari, MD (Study Coordinator); Leonardo Pantoni, MD, PhD, 
Anna Maria Basile, MD, Michela Simoni, MD, Giovanni Pracucci, MD, Monica Martini, MD, 
Luciano Bartolini, PhD, Emilia Salvadori, PhD, Marco Moretti, MD, Mario Mascalchi, MD, PhD. 
The LADIS Steering Committee is formed by Domenico Inzitari, MD (study coordinator), Timo 
Erkinjuntti, MD, PhD, Philip Scheltens, MD, PhD, Marieke Visser, MD, PhD, and Kjell Asplund, 
MD, PhD. 
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Abstract 
 
To evaluate the concordance of a volumetric method for measuring white matter lesion (WML) 
change with visual rating scales t 
he authors selected a stratified sample of 20 elderly people (mean age 72 years, range 61 to 88 
years) with an MRI examination at baseline and at 3-year follow-up from the community-based 
Rotterdam Scan Study (RSS). Four raters assessed WML change with four different visual rating 
scales: the Fazekas scale, the Scheltens scale, the RSS scale, and a new visual rating scale that 
was designed to measure change in WML. The authors assessed concordance with a volumetric 
method with scatter plots and correlations, and interobserver agreement with intraclass 
correlation coefficients.  
For assessment of change in WML, the Fazekas, Scheltens, and periventricular part of the RSS 
scale showed little correlation with volumetrics, and low interobserver agreement. The authors’ 
new WML change scale and the subcortical part of the RSS scale showed good correlation with 
volumetrics. After additional training, the new WML change scale showed good interobserver 
agreement for measuring WML change. 
Commonly used visual rating scales are not well suited for measuring change in white matter 
lesion severity. The authors’ new white matter lesion change scale is more accurate and precise, 
and may be of use in studies focusing on progression of white matter lesions. 
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Introduction 
 
Cerebral white matter lesions (WML) are thought to result from small vessel disease, 
and their presence and severity increase with age and the presence of arterial hypertension.1-3 
Although the clinical significance of these lesions remains to be fully understood, WML have 
been associated with dementia, depression, and stroke.4-6 In healthy elderly people, WML are 
associated with adverse cognitive function and the presence of depressive symptoms.7-9 Patients 
with Alzheimer disease (AD), vascular dementia, and depression have more severe WML than 
controls.4,6 It has been suggested that WML progress gradually over time, and may ultimately 
lead to subcortical vascular dementia and vascular depression or contribute to the clinical 
expression of AD.10 Studies that have determined progression of WML over time are limited, and 
comparison of their findings is difficult due to the use of different visual rating scales for the 
assessment of WML progression.11-13 Evaluation of WML progression is of clinical importance, 
since it is needed to determine the natural course of these lesions, and to study the effect of 
intervention studies. Visual rating scales have proven their value in cross-sectional studies, but 
very little is known about the sensitivity and reliability of these scales for measuring change in 
WML over time. Volumetric methods may provide the most objective assessment method, but 
are often time consuming, and therefore not always feasible in large studies. The objective of the 
present study was to evaluate three commonly used visual rating scales—the Fazekas scale,14 the 
Rotterdam Scan Study (RSS) scale,1 and the Scheltens scale15—in terms of accuracy and 
precision in measuring change of WML in a defined population. We compared the degree of 
concordance with a volumetric method, and the reproducibility of these scales. In addition, we 
introduce a simple visual rating scale that was designed to measure change in WML over time. 
We compared the performance of this WML change scale with the other three visual rating 
scales, and with the volumetric method. 
 
 
Methods 
Subjects 
The scan material used in the present study originates from subjects participating in the 
RSS, a population-based study that was designed to study causes and consequences of age-
related brain changes in elderly people.7 In 1995 through 1996, 1,077 nondemented elderly 
people aged 60 to 90 years underwent a baseline examination that included a cranial MRI scan. 
In 1999 through 2000, 787 of the 973 participants who were alive and eligible (not 
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institutionalized, not moved abroad) were re-examined (response rate 81%). Of these 
participants, 668 underwent a second MRI (response rate 69%). We selected scan pairs from 10 
participants, in a nonrandom manner, to serve as a training set. Additionally, we randomly 
selected 20 participants who had a baseline and follow-up scan, in three strata of baseline 
subcortical WML severity, as assessed with the RSS scale.1 We selected seven participants from 
the first tertile of subcortical WML severity, seven from the second tertile, and six from the third 
tertile to cover the whole range of the WML distribution. The mean age of participants was 72 
years (range 61 to 88 years), 10 (50%) were women, and 8 (40%) had hypertension. The mean 
time between the first and second MRI was 3.3 years (range 2.9 to 4.0 years). 
 
MRI scanning and white matter lesions 
Axial T1, T2, and proton density weighted cerebral MR scans were made on a 1.5-
Tesla scanner (Siemens, Erlangen, Germany). The following pulse sequences were applied: T1 
(700 msec/14 msec/2 [repetition time/ echo time/excitations]), T2 (2,200 msec/80 msec), and 
proton density (2200 msec/20 msec). Slice thickness was 5 mm, with an interslice gap of 1 mm, 
and a matrix size of 192 x 256 pixels. MRI protocols were identical at baseline and at follow-up. 
We defined WML as hyperintense lesions, located in the cerebral white matter, that are visible 
on both T2- and proton density-weighted images, and do not have a hypointense center on proton 
density weighted images (as in lacunes). Lesions were considered periventricular in location 
when directly adjacent to the ventricles; otherwise we considered them as subcortical. If 
periventricular lesions extended 10 mm perpendicularly from the ventricular border, the 
extending part was per definition scored as a subcortical lesion. 
 
Rating scales 
We assessed WML severity at baseline and WML progression with four different 
visual rating scales. The Fazekas scale rates WML both in the periventricular and subcortical 
region on a 0 to 3 scale.14 The Scheltens scale rates WML in the periventricular region on a 0 to 
6 scale, and in the subcortical region on a 0 to 24 scale, on the basis of the size and number of the 
lesions.15 It also includes ratings for basal ganglia and infratentorial areas, which were not used 
in this report. The RSS scale rates WML in the periventricular region on a 0 to 9 scale, and for 
subcortical WML a lesion volume is approximated based on number and size of the lesions.1 In 
addition, we designed and used a new simple scale to measure WML change: the WML change 
scale. In this scale change in WML (-1 decrease, 0 no change, +1 increase) is scored in three 
periventricular locations (frontal caps, lateral bands, occipital caps) resulting in a periventricular 
score of -3 to +3, and in four subcortical locations (frontal, parietal, temporal, and occipital), 
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resulting in a subcortical score of -4 to +4. Increase is defined as the occurrence of a new focal 
lesion or the enlargement of a previously visible lesion; decrease is defined as the reverse (i.e., 
disappearance or shrinkage).  
 
Visual rating system 
All ratings were performed at the VU medical center. The MRI studies were in digital 
format. Four raters (N.D.P., E.C.W.v.S., E.J.v.D., M.S.) analyzed WML on baseline and follow-
up images, using the four different visual rating scales. Raters were blinded to clinical 
information, but not to name, age, and scan year. WML were rated on proton density and T2-
weighted images, by direct scan comparison on a personal computer, using the viewing program 
Radworks (version 5.1, Applicare, Zeist, the Netherlands). To optimize the comparability of the 
baseline and follow-up scans, images had been registered and resliced using the software 
package Mirit, which uses mutual information as optimization criteria.16 After a training session 
in which the four raters in couples assessed 10 scan pairs of the training set, a consensus meeting 
was held among the authors to identify and resolve any possible differences in application of the 
various scales. Following this training stage, each rater then individually scored the 20 series of 
baseline and follow-up MRI studies. The rating scales were always applied in the same order: 
first the Fazekas scale, second the RSS scale, third the Scheltens scale, and finally our WML 
change scale. Raters were aware which was the baseline and follow-up scan, and this may lead to 
bias toward finding a positive change in WML severity. In order to estimate this potential 
systematic measurement error, two raters reassessed the 20 series with the WML change scale in 
the native domain, first blinded to scan date, and 2 weeks later not blinded to scan date. 
 
 
Volumetric assessments 
We used proton density images for the volumetric quantification of WML volume on a 
workstation (Sparc 5; SUN, Palo Alto, CA). One reader identified lesions on the registered 
images, and then determined the areas of the lesions using home-developed software 
(Show_Images, version 3.6.1) in the native domain to avoid artificial enlargement of lesion areas 
due to reslicing. We used a seed growing method to determine WML areas on each slice for 
periventricular WML (frontal caps, lateral bands, occipital caps), and subcortical WML (frontal, 
parietal, temporal, and occipital).17 WML areas were not recorded separately for the right and left 
hemisphere. By summing the areas of each slice multiplied by the interslice distance, we 
calculated total WML volumes for the different regions. The volumetric assessments were 
performed twice, with an interval of 6 months, and the mean value of the two assessments was 
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used in the analyses. The intraclass correlation coefficients reflecting the intrarater agreement for 
the baseline assessment were 0.84 for periventricular and 0.97 for subcortical WML volume, 
with a SD of the difference between the two ratings of 1.4 mL for periventricular and 0.86 mL 
for subcortical WML.18 
 
Data analysis  
For the volumetric assessment, change in WML volume was calculated by subtracting the 
baseline WML volume from the follow-up volume.19 Pearson’s correlation coefficient was used 
to assess the relation between baseline WML severity and WML change in the periventricular 
and subcortical region. For the visual rating scales (Fazekas scale, Scheltens scale, RSS scale), 
change in WML score was calculated by subtracting the baseline from the follow-up rating for 
each rater separately. Progression on the visual rating scales was defined as an increase of 1 point 
or more on the scale. We made scatter plots to visualize the relation between the change in WML 
assessed with the volumetric method (in mL), and the visual rating scales. Furthermore, we 
assessed concordance between visual scales and volumetrics by the nonparametric Spearman’s 
rho. Spearman’s rho values of 0 were considered no relationship between the variables; values 
equal to 1 were considered to reflect perfect correlation. We quantified the interobserver 
agreement on the visual rating scales with intraclass correlation coefficients. The intraclass 
correlation coefficient is the biologic variation between participants divided by the sum of the 
variation between participants and the rater variation. We estimated the possible bias in the 
visual ratings that may have been introduced by being aware which were the baseline and follow-
up images. Bias was expressed as the mean difference in scores on the WML change scale 
between not-blinded ratings and blinded ratings.18 Furthermore, we assessed the 95% limits of 
agreement between the not-blinded and blinded method.  
 
 
Results 
 
WML severity at baseline and change 
The median WML volumes as assessed with the volumetric method were 3.3 mL 
(range 1.6 to 10.4) at baseline and 0.7 mL (range-2.1 to 6.7) increase for the periventricular 
region, and 0.2 mL at baseline (range 0 to 15.2) and 0.1 mL (range -0.4 to 3.5) increase for the 
subcortical region. Mean increase in the periventricular region was 1.4 (SD 2.2) and in the 
subcortical region 0.5 (SD 0.9). This corresponds to a mean WML increase at a rate of 0.42 mL 
per year in the periventricular region and 0.15 mL per year in the subcortical region. Figure 1 
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A. 
 
B. 
Figure 1. White matter lesions (WML) progression in an 88-year-old woman who participated in our study. 
A.  a slice from the baseline study. B.  a corresponding slice from the follow-up study. After 3 1/2 years, 
WML progression has occurred (arrows) in the left and right occipital cap (periventricular region), extending 
into the parietal subcortical regions. 
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Table 2. Correlation between volumetrics and visual rating of WML change assessed by the nonparametric 
Spearman rho test 
  Spearman rho 
WML Rater 1 Rater 2 Rater 3 Rater 4 Mean four 
raters 
Periventricular      
 Fazekas scale 0.29 0.30 NA NA 0.37 
 Rotterdam Scan Study scale 0.42 0.24 NA 0.13 0.27 
 Scheltens scale 0.29 0.40 0.18 0.11 0.39 
 WML change scale 0.55* 0.70† 0.38 0.13 0.62† 
Subcortical      
 Fazekas scale 0.28 0.13 0.43 NA 0.40 
 Rotterdam Scan Study scale 0.62† 0.59† 0.19 0.50* 0.54* 
 Scheltens scale 0.12 0.28 0.25 -0.18 0.27 
 WML change scale 0.65† 0.61† 0.60† 0.35 0.79† 
* p < 0.05, † p < 0.01 
WML = white matter lesion; NA = not assessed because none of the participants showed change on the 
visual scale. 
 
 
shows an example of WML progression in the periventricular and subcortical region. WML 
volumes at baseline were positively correlated with WML change (Pearson correlation 
coefficient 0.70, p = 0.001 for periventricular WML; 0.90, p < 0.001 for subcortical WML).  
Table 1 gives the WML severity at baseline and WML change as well as the number of 
participants with WML progression, as assessed with the different visual rating scales for the 
four raters. Several methods showed on average an increase in WML in both the periventricular 
and subcortical region, but the number of participants showing progression varied largely 
between the different methods applied. 
 
Correlation between volumetric assessment and visual rating scales 
We evaluated the concordance between the volumetric WML change and the change 
assessed with the visual rating scales. This was done separately for the four raters, and after 
averaging the visual rating of the four raters in order to reduce noise due to interobserver 
disagreement. Figure 2 shows the scatter plots of the relationship between WML change 
measured with the volumetric assessment and the visual rating scales (average of four raters) in 
the periventricular and subcortical region. Visual inspection of the scatter plots shows 
comparatively good agreement between the WML change scale and the volumetric method, 
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although the WML change scale tends to overestimate lesion change in the subcortical region 
(figure 2D), and may systematically underestimate lesion change in the periventricular region as 
volume change gets larger (figure 2H). Table 2 gives the nonparametric Spearman’s rho between 
the volumetric method and the four visual rating scales on WML change. Only the subcortical 
part of the RSS scale and the WML change scale showed significant correlation with the 
volumetric method for rater 1, 2, and 3, and for the average of the four raters (see table 2). 
 
Interobserver agreement 
The intraclass correlation coefficients for the interobserver agreement on baseline 
WML severity and change for the visual rating scales including our new WML change scale are 
presented in table 3. Values <0.20 were considered to reflect poor agreement, 0.21 to 0.40 fair 
agreement, 0.41 to 0.60 moderate agreement, 0.61 to 0.80 good agreement, and 0.81 to 1.00 very 
good agreement.18 The interobserver agreement for the baseline ratings on the Fazekas, 
Scheltens, and RSS scales was fair to good for the periventricular region and good to very good 
for the subcortical region (see table 3). However, agreement on change was poor for the Fazekas 
and Scheltens scale, fair for the WML change scale and the periventricular part of the RSS scale, 
and moderate for the subcortical part of the RSS scale. The raters had been using the existing 
rating scales by Fazekas, Scheltens, and the RSS previously and thus were better acquainted with 
them. In a post hoc study that was performed using the new WML change scale after additional 
training, two of the raters rated 200 additional pairs of scans. In this second sample, the 
interobserver agreement was 0.73 for the periventricular region, and 0.72 for the subcortical 
region, indicating good agreement. 
 
Effect of blinding to the scan date 
Mean difference in score on the WML change scale between the not-blinded and 
blinded method were +0.075 (SD 0.40) points in the periventricular region, and -0.025 (SD 0.44) 
in the subcortical region. This indicates there is no substantial bias toward higher progression 
when images are scored with knowledge of which are the baseline and which are the follow-up 
images. The 95% limits of agreement between the not-blinded and the blinded method were (-
0.71 to +0.86) for the periventricular region, and (-0.84 to +0.89) for the subcortical region, 
which suggests that for an individual the not-blinded and blinded method are unlikely to disagree 
more than one point on the WML change scale.  
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Table 3. Interobserver agreement for the visual rating scales for 
baseline and change measurements 
 
Baseline Change 
Periventricular WML   
   Fazekas scale  0.37 0.08 
   Rotterdam Scan Study scale  0.64 0.23 
   Scheltens scale 0.56 0.18 
   WML change scale  0.39 
Subcortical WML   
   Fazekas scale 0.84 0.18 
   Rotterdam Scan Study scale  0.90 0.47 
   Scheltens scale 0.84 0.003 
   WML change scale  0.24 
Numbers are intraclass correlation coefficients. 
WML = white matter lesions. 
 
Discussion 
 
We evaluated three commonly used visual rating scales, and one new simple visual rating scale 
in terms of their ability to measure change in WML severity on MRI. We assessed the 
concordance of the visual assessments with volumetric change, and quantified the reproducibility 
of the scales for measuring WML change. In a stratified sample from a defined population, 
during a 3-year time period, both the volumetric method and the visual rating scales showed, on 
average, an increase in WML. We found significant correlations with volumetric change for the 
subcortical part of the RSS scale and for the new WML change scale. The interobserver 
agreement was moderate for change on the subcortical part of the RSS scale, and fair for the 
WML change scale. In a post hoc study, the interobserver agreement for the WML change scale 
improved to good agreement after observers had become familiarized with the scale. The 
Fazekas, Scheltens, and periventricular part of the RSS scale showed poor correlation with 
volumetric change, and poor to fair interobserver agreement on the change measurements. 
Several methodologic issues need to be addressed. First, there is currently no gold standard for 
the assessment of WML change, and our volumetric method cannot be interpreted as such. 
Characteristics of WMH on imaging 
 79
Second, the comparison between volumetric WML change and WML change measured with 
different visual scales is complicated by differences in type of data (continuous versus 
categorical) obtained with the different methods. We used rank correlation to evaluate the 
relationship between the visual scales and volumetrics. Unlike agreement, correlation is not 
affected by the scale of measurement, but does depend on the range of the quantity of the 
sample.19 Therefore, the presented correlations cannot be interpreted as agreement between the 
visual scales and volumetrics, although they do allow for comparison between the visual scales. 
Third, visual rating was performed side by side, and with knowledge of the time sequence of 
scans, which may have led to some bias toward a higher progression rating. However, we 
evaluated this possible bias in a post hoc analysis, and found that this effect was very small. 
Fourth, registration of the follow-up scans on the baseline scans may have caused blurring effect, 
and although this effect was judged to be small, it may have contributed to higher progression 
rating with the visual rating scales. The Fazekas, Scheltens, and RSS scales were designed for 
cross-sectional assessments of WML. When applied in a cross-sectional fashion these scales 
show both good intra- and interobserver agreement, which largely corresponds to our findings of 
fair to very good interobserver agreement for the baseline assessments.1,15,20 A previous study 
reported that visual rating with the Fazekas and Scheltens scales shows significant correlation 
with quantitative volumetric assessments.20 However, visual assessment of WML change with 
these scales is problematic. There are several explanations for the disappointing performance of 
these scales in measuring WML change. As shown in our and other data sets, baseline WML 
severity is positively correlated with WML change.11 WML that were already rated in the highest 
category at baseline (and which are most likely to progress) cannot contribute to progression on 
these scales due to a ceiling effect. Furthermore, new lesions may develop or lesions may grow 
without crossing the limits of the categories of the scales, and thereby remain below detection on 
the visual scales. The subcortical part of the RSS scale performed better in capturing change, 
most likely because it incorporates the number and size of lesions in more detail, thus avoiding a 
ceiling effect. However, the subcortical part of this scale is elaborate and time consuming. Our 
new WML change scale that was designed to measure WML change not only seemed to be valid, 
but also takes less time to apply. Although agreement on progression initially was fair, it 
approved to good agreement after additional training. We found that during a 3-year period 
WML volume increased at a mean rate of 0.42 mL per year in the periventricular region and 0.15 
mL per year in the subcortical region. These figures on rate of change do not directly reflect the 
rate of change in the population at large because of the way we constructed our sample for this 
validation study. The NHLBI Twin Study reported a mean WML volume increase of 0.38 mL 
per year in 168 individual male twins with a mean age of 72 years,21 which is comparable to the 
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range of our findings on rate of change. When we compare the interobserver agreement on the 
visual scales for the baseline assessments in the present study to those reported in the literature, 
interobserver agreement was comparable for periventricular WML on the Fazekas scale (0.37 
versus 0.35 to 0.74) and for subcortical WML on the RSS scale (0.90 versus 0.88), higher for 
subcortical WML on the Fazekas scale (0.84 versus 0.34 to 0.78) and Scheltens scale (0.84 
versus 0.69), but lower for periventricular WML on the Scheltens scale (0.56 versus 0.71) and 
RSS scale (0.64 versus 0.79 to 0.90).1,15,20 
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Abstract 
 
White matter hyperintensities (WMH) have an effect on cognition and are increased in severity 
among individuals with amnestic mild cognitive impairment (aMCI). The influence of WMH on 
progression of aMCI to Alzheimer’s disease (AD) is less clear. Data were drawn from a three-
year prospective, double blind, placebo controlled clinical trial that examined the effect of 
donepezil or vitamin E on progression from aMCI to AD. WMH from multiple white matter 
regions were scored on MR images obtained at entry into the trial from a subset of 152 study 
participants using a standardized visual rating scale. Cox proportional hazards models adjusting 
for age, education and treatment arm were used to investigate the role of WMH on time to 
progression from aMCI to AD. 55 of the 152 (36.2%) aMCI subjects converted to AD. Only 
periventricular hyperintensities (PVH) were related to an increased risk of AD within three years 
(HR=1.59, 95% CI = 1.24 – 2.05, p-value<0.001). Correcting for medial temporal lobe atrophy 
or the presence of lacunes did not change this relation. PVH are associated with an increased risk 
of progression from aMCI to AD. This suggests that PVH, an MRI finding thought to represent 
cerebrovascular damage, contributes to AD onset in vulnerable individuals independent of 
Alzheimer pathology. 
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Introduction 
 
Recent data suggest that older individuals who have considerable, but circumscribed 
cognitive impairment may be in a transition phase between normal aging and dementia that is 
often denoted as mild cognitive impairment (MCI).1-3 MCI may be divided into multiple 
subtypes.4 Individuals with the amnestic subtype of MCI (aMCI) have memory impairment as 
the primary cognitive deficit and a subsequently high likelihood of progressing to clinically 
probable Alzheimer’s disease (AD).5-8 While it has been suggested that most individuals with 
aMCI are in the earliest stages of AD, cerebrovascular disease (CVD) is also associated with this 
clinical syndrome.9-11 Amongst subjects with extensive white matter hyperintensities (WMH), 
clinically relevant episodic memory impairment may result from dysfunction of working 
memory and of executive control processes.12 Additional studies support this notion by showing 
that WMH are associated with reduced frontal glucose metabolism.13,14 Although substantial 
work has been done to study the role of the AD process on progression from aMCI to dementia, 
studies examining the impact of CVD markers on progression to dementia are more limited and 
have resulted in opposing results.15-17 We therefore examined the impact of WMH on a random 
subgroup of 152 individuals with aMCI. We hypothesized that increased WMH would be 
associated with an increased risk of progressing to AD.  
 
 
Methods 
 
Subjects 
Subjects were drawn from the prospective, double-blind placebo controlled study to 
test the efficacy of donepezil and vitamin E on the progression of aMCI to dementia.18 The 
details of study rationale, design and subject characteristics for the parent study and the MRI sub-
study have been previously described, including description of previous qualitative estimates of 
medial temporal atrophy measures that were used as part of this study.18-20 In brief, 769 
participants were recruited from 69 Alzheimer’s Disease Cooperative Study (ADCS) centers in 
the United States and Canada. Inclusion was based on criteria for amnestic MCI and modified to 
utilize the Logical Memory II subtest of the Wechsler Memory Scale-Revised adjusted for 
education.2,21 Additional requirements included a Clinical Dementia Rating (CDR) scale score of 
0.5 and insufficient impairment to meet National Institute of Neurological and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association criteria for AD 
(NINCDS-ADRDA).22,23 The study was conducted according to Good Clinical Practice 
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guidelines, the Declaration of Helsinki, and the U.S. Code of Federal Regulations title 21 Part 50 
(Protection of Human Subjects) and title 21 Part 56 (Institutional Review Boards). Written 
informed consent was obtained from all participants and study partners who had knowledge of 
the participants’ functional activities. A data and safety monitoring board reviewed the blinded 
safety data every three months during the trial. Subjects were followed-up for three years and 
time to progression to dementia was recorded. AD was the clinically determined etiology for 
dementia in 99% of the subjects. There was no significant treatment effect in the parent study.  
A subset of 195 individuals received a research brain MRI examination at entry to the study as 
part of an ancillary study.24,25 These individuals were selected based solely on their willingness 
to undergo a research MRI and the availability of suitable MRI machinery at clinical sites that 
participated in the parent trial. No other criteria were used to select these subjects and subjects 
from 24 separate sites of the parent study were enrolled into this sub-study. Participants of the 
MRI sub-study closely represented those of the parent study.24 
 
MRI studies 
The imaging protocol included a 3D T1-weighted gradient echo sequence, with 124 
contiguous, 1.6 mm thick coronal slices and 2D proton density (PD) and T2-weighted spin-echo 
sequences with 24 transverse slices, slice thickness 5 mm. MRI data were sent from the 
participating centers to a central location at the Mayo Clinic in Rochester, Minnesota for quality 
check, storage and analysis. For this study, images were stripped from identity data and 
transferred to the Imaging of Dementia and Aging (IDeA) laboratory at the University of 
California at Davis. Of the original 195 scans, WMH from 43 MRIs could not be read due to 
image artefact or incomplete image acquisition of the T2-weighted series, leaving 152 subjects 
with MRI for analysis.  
 
MRI visual rating 
One independent rater (EvS), who was blinded to all demographic and treatment 
related data, applied a semi-quantitative visual rating scale for the analysis of WMH.26 Using this 
scale, deep subcortical WMH were assessed on a 0 – 6 scale in different brain regions, where 
score 0 reflects no WMH, and score 6 confluent lesions. The regions assessed were the frontal, 
parietal, occipital and temporal lobes, basal ganglia and infratentorial regions. A total deep 
WMH score (D-WMH) was composed by summing up the scores of the frontal, parietal, 
occipital and temporal regions (range 0 – 36). In addition, periventricular hyperintensities (PVH) 
were assessed on a scale ranging from 0 –2 scale in three regions (frontal and occipital caps and 
bands). A total periventricular score was composed of the scores of these three regions (range 0 – 
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6). A total WMH score (T-WMH) was created by summing up the scores for D-WMH and PVH. 
Intra-observer variability was good with an intraclass correlation coefficient (ICC) of 0.92. The 
number of lacunes was assessed, where a lacune was defined as a T1-hypointense and T2-
hyperintense CSF-like lesion surrounded by white matter or subcortical gray matter with a 
minimum diameter of 2 mm and was not located in areas with a high prevalence of widened 
perivascular spaces (vertex, anterior commissure). Medial temporal lobe atrophy (MTA) was 
assessed on this data set in an earlier study by one independent rater (PS) on coronal T1 images, 
using a qualitative visual rating scale. 19,27 This scale ranges from 0 – 4 for both left and right 
medial temporal lobe region with higher scores indicative of increased atrophy. The scores for 
the left and right medial temporal lobe region were averaged and used as a general measure of 
medial temporal atrophy.  
 
Statistical analyses 
The primary outcome of interest was time of progression to AD, according to the 
NINCDS-ARDA criteria. Those that had not converted were considered censored at their last 
assessment. Cox proportional hazards models were used to assess the association of qualitative 
white matter ratings with progression to AD. Models were adjusted for age and education. In a 
second step, we added MTA score, treatment arm and number of lacunes to the model to correct 
for the presumed influence of the AD process, treatment effect of donepezil or vitamin E, and 
vascular subcortical changes other than WMH. Kaplan-Meier curves were generated to illustrate 
the findings, by comparing those in the highest 25th percentile of white matter ratings to the 
remainder of the subjects. Mean differences in T-WMH, D-WMH, and PVH scores between 
individuals who converted to AD and those who did not were assessed using Mann-Whitney 
tests. All assumptions of the models were checked both graphically and numerically and were 
met by the data. 
 
Results 
 
Demographics and WMH scores of the total group of 152 subjects, converters (subjects who 
progressed to dementia, n = 55) and non-converters (subjects who did not progress to dementia, n 
= 97) are presented in Table 1. The demographics of this MRI subgroup were similar to parent 
study. The mean age was 72.4 + 6.6 years, the mean educational achievement was 15.0 + 3.0 
years and women made up 55.3% of the sample. Mean baseline MMSE scores (SD) were nearly 
identical between the parent study (27.3 + 1.8) and the current study (27.5 + 1.8). Randomization 
by treatment arm was also well balanced in this study with 30% randomized to donepezil, 32% to 
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vitamin E and 38% to placebo. A total of 55 subjects (36%) converted to dementia over the 3-
year study period. Subjects progressing to dementia were slightly older and included a higher 
percentage of women, but the differences were not significant. Converters, however, performed 
worse on baseline MMSE testing (26.8 + 1.9) than did non-converters (27.9 + 1.6), p < 0.001). 
Mean WMH scores amongst those who converted to dementia also tended to be higher. These 
differences were small and non-significant, although a trend was found for the PVH ratings  
  
 
Table 1. Demographic characteristics of the study group 
 Total group 
(n = 152) 
Converters 
(n = 55) 
Non-converters 
(n = 97) 
Mean age in years, (SD) 72.5 (6.6) 73.4 (6.6) 72.0 (6.7) 
Mean years of education (SD) 15 (3) 15 (3) 15 (3) 
% male 54.2  48.1 57.6 
MMSE (SD) 27.9 (1.8) 26.9 (1.9) 27.9 (1.7) ** 
Mean T-WMH score (SD) 13.4 (8.4) 13.7 (9.7) 13.1 (7.7) 
Mean PVH score (SD) 3.6 (1.2) 3.9 (1.4) 3.5 (1.1) 
Mean D-WMH score (SD) 7.3 (5.4) 7.4 (6.2) 7.2 (5.0) 
Mean basal ganglia score (SD) 1.5 (2.2) 1.5 (2.2) 1.6 (2.3) 
Mean infratentorial score (SD) 0.9 (1.7) 0.9 (1.8) 0.9 (1.7) 
Number of subjects with lacunes 13 7 6 
MTA score (SD) 1.2 (0.8) 1.3 (0.9) 1.1 (0.7)* 
D-WMH: Deep White Matter Hyperintensities, PVH: Periventricular Hyperintensities, T-WMH: Total White 
Matter Hyperintensities. *: p < 0.05, **: p < 0.001 
 
 
 
(p= 0.057). Lacunes were seen in 13 subjects, of which seven converted. Mean T-WMH, D-
WMH and PVH scores were higher in subjects with lacunes (19.4 ml (SD 12.2), 10.6 ml (SD 
7.6), and 4.5 (SD 1.4) respectively against 12.8 ml (SD 7.8), 7.0 (SD 5.1), and 3.5 (SD 1.2) in 
subjects without lacunes). Mean MTA ratings were significantly higher in converters than non-
converters.  
Table 2 shows the additional risk of progression to dementia with each one-point 
increase on the WMH rating scale. Only PVH was significantly associated with an increased risk 
of progression after correcting for age and education. A one-point increase in the rating was 
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associated with a 59% increased hazard of progression. This is also illustrated by figure 1, which 
shows the relationship between the highest quartile of PVH (scores>4) as compared to lower 
scores (scores ≤ 4) and progression to AD over time. Correcting for MTA and number of lacunes 
did not change the significance of this association, even though total PVH and MTA ratings were 
significantly correlated (r = 0.31).  
 
Table 2. Hazard ratios (95% confidence intervals) of increase of 1 point WMH 
 HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Model 3 
PVH 1.59 (1.24 – 2.05)** 1.49 (1.15 – 1.93)* 1.42 (1.08-1.87)* 
D-WMH 1.02 (0.97 – 1.08) 0.99 (0.94 – 1.05) 0.97 (0.92-1.03) 
Basal ganglia 
hyperintensities 
1.06 (0.94-1.20) 1.05 (0.92-1.20) 1.01 (0.88-1.16) 
Infratentorial 
hyperintensities 
1.08 (0.90-1.28) 1.06 (0.89-1.27) 1.01 (0.84-1.21) 
T-WMH 1.03 (0.99-1.06) 1.01 (0.97-1.05) 1.00 (0.96-1.04) 
*: p < 0.05, **: p < 0.001 
Model 1: Age and education included in the model 
Model 2: Age, education, MTA, and treatment arm included in the model 
Model 3: Age, education, MTA, treatment arm, and presence of lacunes included in the model 
 
In order to compare the relative risk for progression to dementia related to PVH and 
MTA, which were rated on different scales, we also fitted the Model 2 after z-score 
transformation. One standard deviation increase in the total PVH rating was associated with a 
64% increased hazard (β=0.49, SE=0.17, p-value=0.003, HR=1.64, 95% CI=1.18-2.27), while 
one standard deviation increase in MTA rating was associated with a 42% increased hazard 
(β=0.35, SE=0.15, p=0.04, HR=1.42, 95% CI= 1.01-1.99). 
Since ApoE genotype was a powerful predictor of progression from MCI to dementia in the 
parent study, we also assessed the relationship between WMH, MTA, and ApoE genotype. Mean 
PVH, D-WMH, T-WMH and MTA scores were significantly higher in ApoE4 allele carriers as 
compared to the non-carriers (p<0.01 for the WMH scores and p = 0.046 for MTA).  
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Figure 1. Relationship between high total Periventricular Hyperintensities score (scores > 4; upper 
25th percentile of scores) and low total Periventricular Hyperintensities score (scores <=4) and 
progression to dementia. 
 
 
Discussion 
 
Our results indicate that PVH, and not deep subcortical WMH, increase the likelihood 
of progressing from amnestic MCI to AD. This is in line with previous cross-sectional studies 28. 
Earlier studies showed influence of PVH on decline in cognition in non-demented elderly and 
risk of dementia29,30. Moreover, the effect of PVH on progression to dementia was unchanged 
after correction for atrophy of the medial temporal lobe suggesting that WMH lesions may have 
effects independent of a presumed AD process and may increase the likelihood of clinically 
evident AD through an additive mechanism. This adds to the growing body of evidence that 
vascular factors increase lifetime risk of AD.15,31-33 
Quantitative measures of WMH and medial temporal lobe atrophy differ notably 
between AD and healthy controls.34 If we assume that most individuals with amnestic MCI have 
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at least some AD pathology, WMH would be expected to increase the likelihood of progression 
to dementia as a second mechanism for brain injury similar to studies of stroke and AD.35-37 
Hypertension is a known risk factor for WMH and can contribute also to cortical atrophy, 
including in the medial temporal lobe. Moreover, since WMH can lead to deficits in cognitive 
areas other than memory, such as executive function or attention, WMH related brain injury may 
result in additional cognitive deficits that would contribute to dementia diagnostic criteria.38 The 
above mentioned studies, however, did not differentiate between deep WMH and PVH, a notion 
that creates confusion and needs clarification for future studies.39 
In our study, subcortical WMH did not substantially add to the risk of progression to 
dementia. There are at least two possible explanations for this finding. First, it may be that 
qualitative estimates of PVH closely estimate total WMH volume.40 Second, it is possible that 
the periventricular region includes functionally important (cholinergic) neural pathways.41,42 Of 
course, the combined effect of total volume and location may be important. Finally, the 
significance of the PVH finding may be a limitation to the qualitative scoring method as 
neuropathological research suggests that the substrate of larger deep and periventricular lesions 
(a likely co-occurrence when PVH scores are high) is similar.43 Irrespective of potential etiology, 
qualitative estimates of PVH seem to reflect the cognitive effect of subcortical subtotal vascular 
disease better than the deep WMH and can therefore serve as a better surrogate marker for 
disease in this population of amnestic MCI subjects. 
ApoE4 genotype has been found to increase the risk of developing AD, presumably by 
increasing amyloid beta protein (Aβ) deposition and enhancing the vulnerability of neurons for 
Aβ.44 We found an association between ApoE4 and increased MTA and WMH scores. ApoE is 
also important to cholesterol metabolism and the ApoE4 genotype is associated with increased 
risk for cardiovascular and possibly cerebrovascular disease.45 The association of ApoE4 with 
both MTA and WMH may, therefore, reflect a role in the development of vascular lesions as well 
as AD pathology and contribute to the apparent association between AD pathology, vascular 
factors and dementia. 
One limitation of this study could be the use of the visual scale for the assessment of 
WMH. Visual scales are not always linear and the effect measured could be limited due to 
ceiling effects.46 Our findings, however, showed a significant relationship of PVH with clinical 
data, indicating that the PVH assessment was sensitive enough in this population. An effect of 
WMH in general on progression from MCI to dementia, however, has not consistently been 
found. Small subject groups and limited number of individuals, who convert to dementia during 
the period of observation, may account for these discrepancies. In addition, we used the MTA 
scale, a qualitative rating scale. Visual MTA scores may not reflect hippocampal atrophy as 
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precise as volumetric measurement of this structure on MRI, although differences between visual 
and volumetric scoring methods seem small with respect to clinical and cognitive 
characteristics.47 
Results of double-blind, placebo-controlled, clinical trials to test efficacy and safety of 
drugs proven to be efficacious in AD, such as cholinesterase inhibitors and vitamin E, are being 
carried out in MCI populations and the first results are becoming available.18,48,49 In animal 
models, permanent oxidative stress is a major contributor to neurodegeneration, leading to the 
investigation of protective effect of vitamin E as anti-oxidative agent.50 However, intervention 
studies have not been able to demonstrate an effect in humans.51 Cholinesterase-inhibitors reduce 
cognitive deficits in AD and VaD, but no effect has been demonstrated in prevention of AD.52   
Whatever the exact mechanism by which PVH exert their influence on progression 
from MCI to AD, these findings could have implications for therapeutic strategies. Effect of 
medication in subjects with neurodegenerative dementia could vary depending on coexisting 
vascular burden.Given the results of this study and others, prevention of vascular lesions such as 
PVH through control of vascular risk factors may prove helpful in reducing the likelihood of 
dementia for at risk populations.17,53,54    
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Appendix 
 
Members of the Alzheimer’s Disease Cooperative Study who participated in this MRI study 
include:  
 
John Adair, University of New Mexico, Albuquerque  
Geoffrey Ahern, University of Arizona, Tucson  
Bradley Boeve, David Knopman, Mayo Clinic, Rochester  
Sandra Black, Sunnybrook Health Sciences, Toronto  
Jeffrey Cummings, University of California, Los Angeles  
Sultan Darvesh, Queen Elizabeth II Health Sciences Centre, Halifax  
Charles DeCarli, Grisel J. Lopez, Kansas University, Kansas City  
Steven DeKosky, University of Pittsburgh  
Ranjan Duara, Wien Center, Miami Beach  
Charles Echols, Barrow Neurology Group, Phoenix  
Howard Feldman, U.B.C. Clinic for Alzheimer’s Disease, Vancouver  
Steven Ferris, Mony deLeon, New York University Medical Center  
Serge Gauthier, McGill Centre for Studies in Aging, Verdun, PQ  
Neill Graff-Radford, Mayo Clinic, Jacksonville, FL  
Danilo Guzman, E. Bruyere Memory Disorder Research, Ottawa  
Jeffrey Kaye, Oregon Health and Science University, Portland  
Alan Lerner, University Hospitals Health System, Cleveland  
Richard Margolin, Vanderbilt University, Nashville  
Marsel Mesulam, Northwestern University, Chicago  
Richard Mohs, Mt. Sinai School of Medicine, Bronx, NY  
John Olichney, University of California, San Diego  
Brian Ott, Memorial Hospital of Rhode Island, Pawtucket  
Elaine Peskind, University of Washington, Seattle  
Nunzio Pomara, Nathan Kline Institute for Psychiatric Research, Orangeburg  
Christopher van Dyck, Yale University School of Medicine, New Haven  
Myron Weiner, University of Texas Southwestern Medical Center, Dallas  
Kristine Yaffe, University of California, San Francisco  
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Abstract 
 
Ischemic cerebrovascular disease (CVD) is expressed on MRI as white matter hyperintensities 
(WMH), lacunes and large vessel infarcts. This study was conducted to investigate specific 
profiles of vascular risk factors associated with each of these CVD types in independently living 
elderly subjects. 
Baseline data of 618 subjects from the multicenter prospective Leukoaraiosis And DISability 
(LADIS) study were used. Mean WMH volume was 21.2 ml (SD 22.6), 48 % of study subjects 
had one or more lacunes, 9 % had one or more clinically silent or minor large vessel infarct. We 
assessed associations between vascular risk factors and CVD with uni- and multivariate linear 
regression (WMH) and logistic regression (lacunes, large vessel infarcts) using the following risk 
factors: age, gender, smoking, history of high cholesterol level, diabetes, peripheral vascular 
disease, hypertension, and heart disease (defined as heart failure, atrial fibrillation, cardiac valve 
disease, and/or myocardial infarction).  
The CVD types were only slightly correlated with each other (0.08 < r <0.23, p < 0.01). Male 
gender was associated with all CVD types, older age and hypertension with WMH volume. 
Diabetes was associated with large vessel infarcts. 
Specific vascular risk profiles can be identified for large and small vessel CVD. These data may 
be used to focus research in future preventive strategies.  
Clinical impact of cerebral vascular lesions 
 101
Introduction 
 
Ischemic cerebrovascular disease (CVD) is expressed on magnetic resonance imaging 
(MRI) as white matter hyperintensities (WMH), lacunes and large vessel infarcts.1 WMH and 
lacunes are thought to reflect small vessel disease, while large vessel infarcts are due to 
obstruction of large cerebral or carotid arteries, thromboembolic or by local arteriopathy.2,3 
WMH seem indicative of incomplete infarction or ischemia, whereas lacunes and large vessel 
infarcts are caused by complete infarction.4  
CVD may give rise to a variety of clinical symptoms and signs, including cognitive 
decline and dementia.5-7 The cognitive profile of patients with WMH and lacunes is typically 
subcortical with impaired executive function and reduced mental speed, whereas large vessel 
infarcts can lead to cortical deficits, including aphasia, alexia, agnosia and memory loss.8-12 
Symptoms of lacunes and large vessel infarcts most often present acutely, whereas deficits due to 
WMH are of more gradual onset. 
Risk factors for individual types of CVD have been studied before. Risk factors of 
WMH that have been repeatedly reported are age and hypertension.13-17 Results with respect to 
other risk factors, including smoking, hypercholesterolemia, diabetes mellitus, and cardiac 
disease have been inconsistent. Hypertension and diabetes mellitus are among the most 
consistently found risk factors for lacunes.18 Older age, smoking, and carotid and cardiac disease 
have also been reported.19,20 Finally, large vessel infarcts have been found to be associated with 
hypertension, heart disease, atrial fibrillation, diabetes mellitus, smoking and hyperlipidemia.21  
It is conceivable that each of these expressions of CVD is associated with a specific 
profile of vascular risk factors. Some vascular risk factors may be associated with several 
expressions of CVD, whereas others are more specific. However, former studies remain 
inconclusive, as no study investigated the associations between vascular risk factors and the three 
CVD types at the same time in one sample. In the current study we assessed the associations 
between vascular risk factors and WMH, lacunes and clinically minor or silent large vessel 
infarcts, respectively, in a large sample of independently living elderly.  
 
 
Materials and Methods 
 
Subjects 
Baseline clinical and radiological data of the Leukoaraiosis And DISability study 
(LADIS) were used. This prospective multicenter multinational project aims to assess the role of 
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WMH on the transition to disability in every day life of elderly subjects who were functioning 
independently at time of enrollment and who had different degrees of WMH. Details on purpose 
and methods of this study were reported previously.22 Since subjects were independent in 
instrumental activities of daily living, the cerebral vascular lesions studied here were not largely 
disabling. At baseline, 639 participants were included and underwent extensive assessment 
including standardized questionnaires on vascular risk factors, neuropsychological tests and 
cerebral MR imaging. 
 
Vascular risk factors 
In the present study we examined the following risk factors: age (dichotomized in 65 – 
74 and 75 – 85 years), gender, smoking (defined as positive in case of current or past smoking), 
history or presence of high blood cholesterol (total cholesterol >200, LDL >130, HDL <35 
mg/dL, and/or hypertriglyceridemia based on serum triglyceride >200 mg/dL, on at least two 
occasions)23, diabetes mellitus (treatment with antidiabetic medications, or at least 8-hour fasting 
plasma glucose ≥ 7.0 mmol/L or 126 mg/dL)24, peripheral vascular disease (symptomatic disease 
presenting as intermittent claudication and/or critical leg ischemia)25, hypertension (subjects 
receiving antihypertensive treatment or with values ≥140/90 mmHg, based on measurements 
taken on several separate occasions)26, heart disease, defined as presence of at least one of the 
following: symptoms of heart failure, objective evidence of cardiac dysfunction and response to 
treatment directed toward heart failure27, atrial fibrillation (based on history and/or available 
clinical records as ECG characterized by the presence of rapid, irregular, fibrillatory waves that 
vary in size, shape and timing, usually associated with an irregular ventricular response)28, 
cardiac valve disease (presence of one of more of the following: aortic stenosis, chronic aortic 
regurgitation, mitral stenosis, mitral regurgitation, multiple valve disease,  prosthetic heart 
valves), or myocardial infarction (documented by history, ECG or cardiac enzymes)29. Data on 
high cholesterol were missing in 20 subjects, on smoking in 1, on diabetes in 4, on peripheral 
vascular disease in 6, on hypertension in 2, and on heart disease in 6. 
 
MRI 
MRI studies consisted of a sagittal or coronal T1-weighted magnetization prepared 
rapid acquisition gradient echo (MPRAGE) sequence with 1-1.5 mm slices and axial T2 and 
Fluid Attenuated Inversion Recovery (FLAIR) images of 5 mm thickness. WMH were measured 
semi-automatically by a single rater (ECWvS) on the FLAIR images using a home-developed 
seed-growing program (Show_Images, version 3.6.1) on a Sparc 5 workstation (SUN, Palo Alto, 
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Calif.).30 Briefly, lesions were marked manually and automatically outlined based on the locally 
set threshold for upper and lower intensity values, rendering a WMH volume. WMH volume 
measurements were not available for 21 subjects due to insufficient scan quality. Total number of 
lacunes was assessed on the MPRAGE, a lacune being defined as a hypointense focus of at least 
3 mm in the largest diameter, surrounded by white matter or subcortical gray matter, and not 
located in areas with a high prevalence of widened perivascular spaces (vertex, anterior 
commissure). Large vessel infarct was defined as a parenchymal defect in an arterial territory 
involving the cortical gray matter.31  
 
 
Statistical analyses 
Associations among different types of CVD were assessed using Spearman’s rank 
correlation analysis. Univariate and multivariate linear (WMH) and logistic (lacunes, large vessel 
infarcts) regression analyses were performed with dichotomized vascular risk factors as 
independent variables and WMH, lacunes and large vessel infarcts as the dependent variables. 
WMH volumes (ml) were used and the number of lacunes and large vessel infarcts was 
dichotomized in zero, or at least one. First, we performed univariate models for each risk factor 
separately (Model 1). Second, all risk factors were entered simultaneously (Model 2), Finally, the 
two other CVD types were entered as additional covariates in the multivariate model (Model 3).   
 
 
Results 
 
In the present study, 618 subjects were analysed, of which 278 (45%) males and 270 
(44%) in the older age group. Mean WMH volume was 21.2 ml (SD 22.6, range 0.7 – 156.1). 48 
% of study subjects had one or more lacunes, 9 % had one or more large vessel infarct. Location 
of the infarcts was frontal in 12 subjects, parietal in 21, occipital in 16, temporal in 11, 
infratentorial in 13, and in the basal ganglia in 4. The three CVD types were only slightly 
correlated (0.08 < r <0.23, p < 0.01). The prevalence of risk factors in the study sample is shown 
in figure 1. Hypertension was very common with a frequency of 70%. In addition, there was a 
relatively large group of subjects with a positive history of smoking and hypercholesterolemia. 
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Figure 1. Number of subjects in each risk factor category.  
PVD: peripheral vascular disease 
 
 
Univariate linear regression analyses showed that WMH volume was associated with older age, 
male gender, and smoking (table 1, model 1). In the multivariate analysis, older age, male gender 
and hypertension were significant predictors (model 2). When lacunes and large vessel infarcts 
were additionally corrected for, age and gender remained statistically significant (model 3). 
Univariate logistic regression analyses showed positive associations for older age and male 
gender with the presence of lacunes (table 2, model 1). Male gender was a significant predictor in 
the multivariate analyses (model 2 and 3) and together with older age when corrected for other 
CVD types (model 3). 
The presence of large vessel infarct was related to several risk factors in univariate 
logistic regression analyses (table 3, model 1). In the multivariate analyses, the associations with 
male gender and diabetes remained significant (model 2 and 3). 
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Table 1. Associations between vascular risk factors and WMH 
risk factor  Mean WMH 
volume (SD) 
Model 1 Model 2 Model 3 
 
Age (years) 65 – 74 18.0 (19.7)    
 75 – 85 25.2 (25.5) 7.2 (1.8)** 7.8 (1.8)** 7.9 (1.8)** 
Gender female 18.1 (18.2)    
 male 25.0 (26.6) 6.9 (1.8)** 6.6 (1.9)** 4.4 (1.9)* 
Smoking no 19.5 (21.4)    
 yes 23.2 (24.0) 3.7 (1.8)* 1.9 (1.9) 2.1 (1.8) 
Hyper- no 22.0 (24.9)    
cholesterolemia yes 20.3 (20.5) -1.7 (1.9) -0.8 (1.8) -1.6 (1.8) 
Diabetes  no 20.8 (22.7)    
 yes 22.7 (22.5) 1.9 (2.6) 1.5 (2.6) -0.1 (2.6) 
Peripheral  no 20.8 (22.5)    
vascular disease yes 20.7 (17.6) -0.1 (3.5) -2.2 (3.6) -3.0 (3.5) 
Hypertension no 18.7 (22.5)    
 yes 22.1 (22.6) 3.4 (2.0) 4.1 (2.0)* 3.1 (2.0) 
Heart disease no 20.4 (22.6)    
 yes 24.1 (23.0) 3.7 (2.2) 1.5 (2.2) 0.7 (2.2) 
Data are presented as β (se). Model 1 represents univariate linear regression analyses. Model 2 represents 
multivariate analysis with mentioned risk factors only. Model 3 represents multivariate linear regression 
analysis including mentioned risk factors, lacunes and infarcts included in the model. *: p ≤ 0.05, **: p ≤ 
0.001 
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Table 2. Associations between vascular risk factors and lacunes 
risk factors  %  
lacunes 
Model 1 Model 2 Model 3 
 
Age (years) 65 – 74 51 0.7 0.8 0.7 
 75 – 85 43 (0.5 – 1.0)* (0.5 – 1.1) (0.5 – 0.9)* 
Gender female 40 2.0 1.8 1.6 
 male 57 (1.4 – 2.7)** (1.3 – 2.6)** (1.1 – 2.4)** 
Smoking no 45 1.3 1.0 1.0 
 yes 51 (0.9 – 1.8) (0.7 – 1.5) (0.7 – 1.4) 
Hyper- no 45 1.2 1.2 1.2 
cholesterolemia yes 50 (0.9 – 1.7) (0.9 – 1.7) (0.8 – 1.8) 
Diabetes no 47 1.3 1.1 1.0 
 yes 53 (0.8 – 2.0) (0.7 – 1.8) (0.6 – 1.7) 
Peripheral  no 47 1.7 1.4 1.4 
vascular disease yes 61 (0.9 – 3.3) (0.7 – 2.8) (0.7 – 2.8) 
Hypertension no 42 1.4 1.4 1.3 
 yes 50 (1.0 – 1.9) ( 0.9 – 2.0) (0.9 – 1.9) 
Heart disease no 46 1.3 1.1 1.0 
 yes 63 (0.9 – 1.9) (0.7 – 1.6) (0.7 – 1.6) 
Data for models 1 – 3 are presented as OR (95% CI).  Model 1 respresents univariate logistic regression. 
Model 2 represents multivariate logistic regression with mentioned risk factors only. Model 3 represents 
multivariate logistic regression with mentioned risk factors, WMH, and infarcts.  
*: p ≤ 0.05 , **: p ≤ 0.001 
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Table 3. Associations between vascular risk factors and large vessel infarcts 
risk factors  % 
infarcts 
Model 1 Model 2 Model 3 
 
Age (years) 65 – 75 8 1.3 1.7 1.5 
 75 – 85 11 (0.8 – 2.3) (0.9 – 3.1) (0.8 – 2.7) 
Gender female 5 3.3 3.5 2.9 
 male 15 (1.8 – 6.0)** (1.8 – 6.7)** (1.5 – 5.7)** 
Smoking no 9 1.1 0.8 0.7 
 yes 10 (0.6 – 1.8) (0.4 – 1.4) (0.4 – 1.3) 
Hyper- no 8 1.5 1.6 1.7 
cholesterolemia yes 11 (0.8 – 2.5) (0.9 – 1.9) (0.9 – 3.2) 
Diabetes no 7 3.5 2.8 2.8 
 yes 21 (1.6 – 6.4)** (2.5 – 5.5)** (1.4 – 5.4)** 
Peripheral  no 9 1.7 1.4 1.4 
vascular disease yes 14 (0.7 – 4.2) (0.5 – 3.8) (0.5 – 4.0) 
Hypertension no 5 2.2 1.7 1.6 
 yes 11 (1.1 – 4.4)* (0.8 – 3.7) (0.7 – 3.4) 
Heart disease no 8 2.2 1.7 1.8 
 yes 16 (1.2 – 3.9)** (0.9 – 3.2) (1.0 – 3.5) 
The presence of infarcts is presented as percentage. Data for models 1 – 3 are presented as OR (95% CI).  
Model 1 respresents univariate logistic regression. Model 2 represents multivariate logistic regression with 
mentioned risk factors only. Model 3 represents multivariate logistic regression with mentioned risk factors, 
WMH, and lacunes. *: p ≤ 0.05, **: p ≤ 0.001 
 
 
Discussion 
 
In the current study, risk factors for different types of CVD were sought. 
Concommitant cerebrovascular disease was into account in the analyses and results were 
comparable with those of previous population-based studies in which risk factors for WMH, 
lacunes and large vessel infarcts were studied separately with respect to the fact that age and 
hypertension were associated with WMH volume and diabetes mellitus with large vessel 
infarcts14,16,20,32-35. We found older age, male gender, and hypertension to be independent risk 
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factors for WMH, male gender for lacunes, and male gender and diabetes mellitus for clinically 
minor or silent large vessel infarcts. In addition, our data suggest that male gender is a general 
risk factor for CVD, which is in congruence with former studies on risk factors for 
cardiovascular disease as well as cerebrovascular disease.36,37 Gender differences could be partly 
due to differences in prevalence of risk factors. However, in the multivariate analyses we 
corrected for the prevalence of other risk factors. Alternatively, men may be more susceptible to 
the effect of vascular risk factors.38 Finally, a cardioprotective role of estrogens until menopause 
and a later onset of vascular disease in women could also partly explain the differences between 
males and female.39,40 
The design of this study has the advantage that a large number of subjects were 
included, examined and scanned in an identical fashion, information on risk factors was collected 
uniformly and contributions of the risk factors could be compared directly. One of the limitations 
of the study may be the subject selection. The stratification by WMH may prevent 
generalizability of the results to a general population of elderly. However, the LADIS sample 
likely suits with the patient population with WMH encountered in clinical practice because of the 
broad range of reasons for referral. In addition, subjects who were not independently living could 
not be included. Cerebrovascular disease leading to major deficits was therefore not present in 
the LADIS study population. The large vessel infarcts analysed here were clinically silent or 
minor. 
 This study shows different vascular risk profiles for the large and small vessel CVD 
categories. Except the administration of thrombolytic medication in the first hours after ischemic 
stroke, therapeutic strategies for ischemic disease are focused on prevention of recurrence of 
ischemic events. This includes strict control of blood pressure and correction of hyperlipidemia. 
Preventive treatment can be potentially more focused when risk factor profiles are known. 
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General discussion 
 
Vascular lesions on MRI 
The effect of compromised vascularisation of the brain can be visualized on MRI and 
has several appearances. The different T1- and T2-weighted sequences have their own qualities 
and when combined give complementary information on the characteristics and probable cause 
of the ischaemic pathology. This may be important to fulfill diagnostic criteria, as mentioned 
below, and changes the role of neuroimaging from excluding possibly treatable causes of 
cognitive decline to a more diagnostic approach. T1-weighted images reveal lacunes and cortical 
infarcts, FLAIR is best suited for the assessment of WMH and we found that conventional T2-
weighted images are preferred in the assessment of WMH in the thalamus and infratentorial 
regions. In addition, T2* sequences (e.g. gradient-echo) can be used for the detection of 
microbleeds. An imaging protocol using T1, T2, T2* and FLAIR images may therefore 
optimizes diagnostic capabilities of MRI for VaD (table 1).  
 
Diagnosing VaD 
For diagnosing VaD the NINDS-AIREN criteria are the most recent and  widely used criteria. To 
fulfill a diagnosis of VAD according to those criteria, a subject is required to be a) demented, b) 
have clinical and radiological signs of vascular disease and c) have an onset of symptoms within 
a couple of months after the vascular ictus.1 The criteria were originally designed for research 
purposes in 1993, but are now also widely used in patient care. Already in 1993, the authors 
recognized the added value of neuroimaging and some form (CT or MRI) was required for the 
diagnosis. The criteria include a radiological part, which includes a list of vascular lesions 
thought to be leading to cognitive deficits. This list is complex; only lesions in specific areas of 
the cerebrum and of certain severity are regarded sufficient to lead to VaD. We demonstrated that 
the radiological part of the NINDS-AIREN criteria has poor agreement between raters and we 
hypothesized that this may at least be partly due to lack of description of the areas and severity of 
the lesions. Operationalization (using a manual on how to apply the criteria and used to create 
uniformity between raters) only improved agreement in raters that were already experienced in 
the assessment of vascular lesions on MRI. Operationalization does not change criteria and 
therefore can not address all problems related to diagnosing VaD. Further work is certainly 
needed to elaborate on the radiological evidence needed to demonstrate VaD. 
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Table 1. Example of imaging protocol for the detection of cerebral vascular lesions 
Coronal 3D T1 gradient echo TR 15 ms 
 TE 7 ms 
 TI 500 ms 
 Slice thickness 1 mm 
 Flip-angle 15-30 degrees 
   
Axial T2 Turbo Spin Echo TR 4600 ms 
 TE 119 ms 
 Slice thickness 3-5 mm 
   
Axial FLAIR  TR 9000 ms 
 TE 105 ms 
 TI 2200 ms 
 Slice thickness 3-5 mm 
   
Axial T2* gradient-echo TR 650 ms 
 TE 15 ms 
 Slice thickness 3-5 mm 
 Flip-angle >20 degrees 
TR = repetition time, TE = echo time, TI = inversion time 
 
 
 
Based on observations of patients with multiple infarctions and dementia, the stepwise 
progression of cognitive decline and the presence of other focal neurological deficits were 
adopted in the criteria. Extensive WMH as a cause of VaD only gained general recognition since 
the 1980’s with the availability of cerebral CT and MR imaging. In the years after 1993, when 
imaging became available on a wider scale and could be used for patient care as well as research, 
it was more obvious that VaD due to WMH is in fact the most common form of VaD2,3, and that 
the requirements of a stepwise progression and other focal neurological deficits are typically not 
applicable to this group of VaD subjects.  
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Radiological considerations of WMH 
Pathology / etiology 
WMH are considered to be an expression of small vessel disease. Arteriolopathy of the 
small vessels penetrating the white matter may compromise the supply of oxygen, leading to 
subtotal ischemia and partial demyelination. The ensuing alterations in the biochemical 
properties of the tissue lead to altered relaxation behavior facilitating the visibility of WMH on 
MRI.4 Neuropathological studies showed that WMH, as seen on MRI, correspond with 
rarefaction of myelin, gliosis, and axonal loss to a varying degree.4-6 Further work is needed to 
improve the possibilities to differentiate WMH into more benign and more severe types of tissue 
damage, and thereby hopefully improving the clinico-radiological associations. 
 
Assessment of lesion distribution and severity 
Several methods exist to measure severity of WMH. Visual rating scales are quick, 
easily applicable and interobserver reliability is good for most used scales. On the other hand, the 
scales do usually not provide details on size and location of the lesions and most are not linear. 
To obtain lesion volume, a computerized method can be used. Most of these techniques are semi-
automated, meaning that some operator interference is necessary, leading to time-consuming 
measurements. In addition, these volumetric methods require a designated computerized 
environment, which has limited availability. We demonstrated in chapter 3.1 that correlations 
with clinical data are dependent of the method used, and the volumetric methods seem more 
sensitive. Especially in small study samples this seems therefore the preferred technique. In 
addition, computerized volume measurements can be used in several applications: by combining 
computerized lesion outlines with an anatomic map (which can be registered to the subject 
space), it is possible to generate regional lesion loads. When intracranial volumes are assessed, 
these can be included in the analyses. Further work is needed to automate lesion detection using 
computer algorithms, which provides plausible results in some labs, but typically are difficult to 
apply to images generated by other MR scanners.7,8   
 
Clinical considerations of WMH 
Research has shown that WMH can lead to memory problems, mood disorders, gait 
disturbances and bladder control dysfunction.9-13 It was hypothesized that this could be due to the 
disruption of axons, running through the white matter regions, and hereby change connections 
between cortical regions and other parts of the CNS.14,15 On the other hand, ischemia of basal 
forebrain cholinergic nuclei, basal ganglia or white matter that have extensive cholinergic 
cortical projections may result in cholinergic deficits and clinical symptoms.16,17 The severity of 
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the WMH correlates with clinical symptoms, but there are individuals with extensive and 
confluent lesions without significant clinical correlates, although they are are at greater risk for 
becoming impaired in daily life.18-20 The recruitment of other cortical areas than originally 
designed for the task can possibly mask the deficits.21 WMH can lead to cognitive deficits to 
such extend that a vascular dementia syndrome becomes present. There are, however, also 
indications that these lesions contribute to the development of AD.22 The exact mechanisms are 
not completely understood and a number of possible causes have been postulated. WMH might 
lead to deficits in cognitive areas other than memory, such as executive function or attention, and 
can therefore contribute to AD in an earlier stage than by AD pathology alone.23 Another 
explanation could be that vascular lesions can lead to enhanced neuronal degeneration. Recently, 
it was shown that oxidative stress was one of the earliest pathological changes in AD, possibly 
leading to cell dysfunction and degenerative changes.24,25 
 
 
Future Directions 
 
Diagnosing VaD 
We were able to demonstrate that operationalization of the criteria for VaD improves 
interobserver reliability in experienced observers to a clinically acceptable level. Further work 
however, is needed to refine the radiological criteria, and make them more widely applicable in a 
reliable fashion. Since good interobserver reliability is needed for criteria to clinically diagnose a 
disease, we suggest the current criteria to be revised with the incorporation of exact imaging 
criteria. Second, the knowledge that the subcortical subtype is more prevalent than previously 
believed and the clinical course and signs that are applicable to the cortical subtype do not apply 
to the subcortical form should in our opinion be incorporated in the definition of VaD26.  
 
 
 
Imaging and assessment of WMH  
We showed that the method used for the assessment of WMH can increase statistical power in 
studies describing the relationship of WMH with clinical parameters. It can be hypothesized that 
this is also true for the evaluation of risk factors for WMH. If automated quantitative 
measurements will be further developed, precision might be improved, and operator assistance 
and time of assessment can be reduced. This offers the possibility of monitoring disease 
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progression and effects of therapeutic interventions. Other imaging techniques, such as diffusion 
fiber tracking techniques, may show the anatomical connections of different cortical regions 
through white matter tracts and provide more information on the (degree of) disruption of 
specific fiber tracts affected by WMH and the loss of function that follows.  
 
Treatment of VaD  
Symptomatic treatment has been focused on the cholinergic deficits that have been found in 
VaD. Acetylcholine can induce vasodilation and studies on the effect of cholinesterase inhibitors, 
approved for the treatment of AD, have shown beneficial effects on cognition and daily 
functioning in subjects with VaD as well, although the effects were not as large as in individuals 
with AD.17,27-29 Memantine, a N-methyl-d-aspartate receptor antagonist possibly preventing 
neurodegeneration by reducing the cells’ pathologically increased sensitivity to glutamate, leads 
to modest improvement of cognition and behavior in individuals with mild to moderate VaD.30,31  
A more causal therapy for VaD would be the prevention of (further) vascular damage to the 
brain. Several risk factors have been identified, some of which are amenable to treatment. A 
reduction in the incidence of dementia by treating hypertension has been reported.32 Potential 
secondary preventive agents such as NSAID's are also subject of study. In two retrospective 
studies, subjects with VaD using antiplatelet or anticoagulant medication had a longer life 
expectancy that those without.33,34 Caution should be taken not to generalize the results to the 
entire VaD population, since subjects with microbleeds possibly are at greater risk of developing 
hemorrhagic strokes and have not been studied separately. The first study only included 
individuals with ischemic VaD and the second study included 79 VaD patients with the number 
of subjects with microbleeds not mentioned. In longitudinal designs, the effect of prevention of 
progressing dementia by changing vascular risk factors still needs to be studied.  
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Summary 
 
The incidence of dementia is increasing to the stunning number of 30.000 new cases each 
year in the Netherlands. Despite progress in knowledge of the several forms of dementia, causal 
therapies are yet not available at this moment. However, several therapeutic agents are being 
investigated in different groups of dementia and it is therefore important to be able to 
differentiate between different causes of dementia. This especially holds for the distinction 
between Alzheimer’s disease versus vascular dementia.  
In the past, brain imaging was regarded as optional, mainly to exclude possibly surgically 
treatable causes of dementia, such as mass lesions. Today imaging can contribute to specifically 
diagnose the illness underlying a dementia syndrome, for example by demonstrating medial 
temporal lobe atrophy in Alzheimer’s disease. MRI is very sensitive to vascular lesions. With 
T1-weighted series, cortical infarcts and lacunes can be visualized. T2-weighted sequences, like 
Fluid-Attenuated Inversion Recovery (FLAIR) and dual-echo Turbo Spin Echo (TSE) are used 
to show subcortical lesions; FLAIR is able to distinguish between WMH on one hand and 
lacunes and perivascular spaces on the other, while TSE is preferred for the basal ganglia (and 
thalamus) and infratentorial regions. 
VaD is thought to be the second most common type of dementia. The NINDS-AIREN 
criteria for VaD are the most recent and widely used. These criteria contain a radiological part, 
necessitating evidence of vascular disease on brain imaging. In chapter 2.2 we showed that 
overall interobserver agreement of these radiological criteria is poor (Cohen’s κ 0.29), and that 
operationalization only improves agreement between already experienced raters of vascular 
lesions on MRI (κ = 0.62), but that it does not affect agreement between raters who are not 
trained in scoring vascular lesions (from κ = 0.17 to κ = 0.18 after operationalization). 
According to the NINDS-AIREN radiological criteria for VaD, bilateral vascular lesions in 
the thalamus can account for a VaD syndrome. In Chapter 2.3, axial TSE imaging is compared 
to axial FLAIR with respect to these thalamic lesions. In a blinded review of MRIs of 73 
subjects, meeting the NINDS-AIREN radiological criteria of VaD, TSE was found to be more 
sensitive. Using FLAIR, only 55% of the probable vascular lesions are detected. For TSE, this is 
97%. Those results signify that, when applying the NINDS-AIREN criteria, FLAIR should not 
be the only T2-weighted sequence. 
WMH can be assessed qualitatively, using a visual scale, or quantitatively, with volumetric 
methods. Chapter 3.1 shows the characteristics of several visual scales for WMH in comparison 
with a semiautomated volumetric assessment. The visual scales appear to have ceiling effects 
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and their relationship with increase in WMH volume is not linear, possibly compromising their 
ability to detect differences between groups. Several visual scales for the assessment of WMH 
were investigated with respect to their power of detecting WMH changes over time in chapter 
3.2. It is reported that on 3-year interval MRIs of subjects with varying degree of WMH, the 
rating scales that are developed for the assessment of WMH on cross-sectionally, are largely 
unable to pick up changes in WMH burden over time within subjects. Volumetric assessment or 
the use of a visual rating scale, specifically designed to detect change over time, are more 
sensitive to progression of WMH, and are therefore preferred in longitudinal studies. 
Vascular lesions can lead to VaD, but there is a growing body of evidence that they also 
might play a role in the etiology of AD. Vascular lesions are more common in subjects with AD 
compared to healthy controls of the same age. We investigated the presence of WMH in a 
sample of subjects with amnestic MCI, which is regarded by some as a transition phase between 
normal aging and AD, and who were followed up over a period of three years. Using a visual 
rating scale, WMH was assessed in several brain regions: subcortical, periventricular, in the 
basal ganglia, and infratentorial. We found that WMH located in the periventricular regions was 
significantly more prevalent in the individuals who later progressed to AD. This may indicate 
that vascular factors influence the development of degenerative dementia such as AD. 
Ischemic vascular brain lesions can be divided into cortical (large vessel) infarcts, lacunar 
(subcortical) infarcts and WMH (subtotal ischemia). In chapter 4.2 we investigated risk factor 
profiles of these three types of CVD and found that male gender is a risk factor for all of these 
CVD types. 
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Samenvatting  
 
De incidentie van dementie neemt toe tot 30.000 nieuwe gevallen per jaar in Nederland. 
Ondanks toename van kennis over de verschillende vormen van dementie is een causale 
behandeling nog niet beschikbaar op dit moment. Omdat diverse medicijnen worden onderzocht 
op werkzaamheid, is het belangrijk om onderscheid te kunnen maken tussen de verschillende 
vormen van dementie, met name tussen de ziekte van Alzheimer (AD) en vasculaire dementie 
(VaD).  
Voor het stellen van de diagnose dementie was het verrichten van beeldvorming van de 
hersenen in het verleden optioneel en met name gericht op het uitsluiten van mogelijk 
chirurgisch behandelbare oorzaken, zoals ruimte-innemende processen. Tegenwoordig kan 
beeldvorming bijdragen om de onderliggende ziekte bij dementie te diagnoticeren, zoals het 
aantonen van atrofie van de mediale temporaal kwab bij AD. Met MRI kunnen vasculaire lesies 
zeer goed worden aangetoond. Met T1-gewogen opnamen kunnen corticale en lacunaire 
infarcten zichtbaar worden gemaakt. T2-gewogen series, zoals Fluid-Attenuated Inversion 
Recovery (FLAIR) en dual-echo Turbo Spin Echo (TSE) kunnen worden gebruikt om 
subcorticale lesies in beeld te brengen; met FLAIR kan onderscheid worden gemaakt tussen 
witte stof hyperintensiteiten (WMH) enerzijds en lacunaire infarcten en perivasculaire ruimten 
anderzijs, terwijl TSE het meest geschikt is voor de beoordeling van de basale kernen (en 
thalamus) en infratentoriële gebieden.  
Er wordt aangenomen dat VaD de op één na meest voorkomende oorzaak is van dementie. 
De International Workshop of the National Institute of Neurological Disorders and Stroke 
(NINDS) and the Association Internationale pour la Recherche et l’Enseignement en 
Neurosciences (AIREN) criteria zijn de meeste recente en meest gebruikte criteria voor VaD. Ze 
bevatten een radiologisch deel, waardoor beeldvorming nodig is om aan deze criteria te kunnen 
voldoen. In dit proefschrift wordt beschreven dat de overeenstemming tussen personen die deze 
radiologische criteria toepassen laag is (Cohen’s κ 0.29), en dat het operationaliseren van de 
criteria de overeenstemming alleen vergroot tussen personen die al ervaring hebben met het 
beoordelen van vasculaire lesies op MRI (κ = 0.62). Overeenstemming tussen beoordelaars 
zonder deze ervaring neemt hierdoor niet toe (van κ = 0.17 tot κ = 0.18) (hoofdstuk 2.2). 
Vasculaire lesies in de thalamus kunnen, volgens het radiologische deel van de NINDS-
AIREN criteria, leiden tot VaD. In hoofdstuk 2.3 bleek TSE sensitiever dan FLAIR voor de 
detectie van deze lesies bij de beoordeling van  MRI scans van 73 personen, die voldeden aan de 
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NINDS-AIREN radiologische criteria. Met FLAIR werd 55% van de lesies gevonden, met TSE 
97%. Dit suggereert dat voor de beoordeling van vasculaire lesies FLAIR niet de enige T2-
gewogen serie zou moeten zijn.  
WMH kunnen kwalitatief beoordeeld worden, door middel van een visuele schaal, of 
kwantitatief, met volumetrische methoden. In hoofdstuk 3.1 worden de kenmerken van diverse 
visuele schalen en een semi-automatische volumetrische methode beschreven. De visuele 
schalen blijken plafond-effecten te vertonen en hoogte van WMH score met behulp van deze 
schalen houdt niet lineair verband met het WMH volume. Hierdoor zou het onderscheidend 
vermogen van de schalen om verschillen tussen groepen te detecteren verminderd kunnen zijn.  
Diverse visuele schalen voor de beoordeling van WMH waren ook beoordeeld met betrekking 
tot hun vermogen om verschillen in tijd te detecteren. In hoofdstuk 3.2 wordt beschreven dat de 
visuele WMH schalen, die ontwikkeld zijn voor de cross-sectionele beoordeling van WMH, 
grotendeelds niet in staat zijn om veranderingen in volume van WMH, beoordeeld op MRI’s met 
een drie-jaar interval van personen met verschillende ernst van WMH, in score tot uitdrukking te 
brengen. Volumetrische methoden en een visuele schaal die specifiek voor de beoordeling van 
verandering van WMH is ontworpen zijn sensitiever voor progressie van lesies en daarom te 
verkiezen in longitudinale studies. 
Cerebrale vasculaire lesies kunnen leiden tot VaD, maar er zijn steeds meer aanwijzingen 
dat ze ook een rol spelen bij de ontwikkeling van AD. Ze komen vaker voor bij personen met 
AD in vergelijking met leeftijdgenoten zonder de ziekte. De aanwezigheid en uitgebreidheid van 
WMH werd beoordeeld in een groep personen met amnestische MCI, hetgeen mogelijk een 
transitiefase is tussen normale veroudering en AD. Met een visuele schaal werden WMH 
gescoord in verschillende hersengebieden (subcorticaal, periventriculair, in de basale kernen en 
infratentorieel) op baseline MRI (hoofdstuk 4.1). Personen die na 3 jaar follow-up AD hadden 
ontwikkeld, bleken significant vaker WMH in de periventriculaire gebieden te hebben dan de 
personen die na 3 jaar geen AD hadden.  
Ischemische cerebrale vasculaire lesies kunnen worden onderverdeeld in corticale infarcten, 
lacunaire (subcorticale) infarcten en WMH (subtotale ischemie). In hoofdstuk 4.2 worden de 
vasculaire risicoprofielen beschreven van deze drie typen CVD. Mannelijk geslacht was een 
risicofactor voor alle typen CVD.
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